Terms,CUIs,Number
heart failure ( class l - lll ),C0018801;C0018802;C4554158,0/10465
duration of hypertension  n ( % ),C0449238;C0449238;C2926735;C2926735,1/10465
type nmbr diabetes 一 no . ( % ),,2/10465
tofacitinib nmbr mg bid [n = nmbr |,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,3/10465
high - density lipoprotein cholesterol mean ( mg / dl ± sd ),,4/10465
temporary discontinuation of study drug,C0205374;C0205374;C0205374;C1548539;C1548539;C1548539;C3245481;C3245481;C3245481,5/10465
death  mi  idr  st  or any timi bleeding,C0011065;C1306577;C4082313;C4552775,6/10465
race and ss at baseline,C0034510;C1706779;C3853635,7/10465
high intensity,C4081854,8/10465
prior percutaneous coronary intervention  n ( % ),C0332152;C2826257,9/10465
pre - randomization pci,C0332152;C0740175;C2257086;C3669034,10/10465
p  subgroup *,C0369773;C2603361,11/10465
hosji fcrhypoglycemia,,12/10465
apixaban vs . placebo,C1831808,13/10465
medication use — no . ( % ),,14/10465
second prior mi,C0205436;C0205436;C0457385;C0457385;C0565930;C0565930;C1561503;C1561503;C1705190;C1705190,15/10465
subarachnoid hemorrhage,C0038525,16/10465
total invasive cancer,C0439175;C0439810,17/10465
acute stent thrombosis,C0205178,18/10465
alteplase ( n = nmbr ),C0032143,19/10465
relative decrease > nmbr %,C0080103;C0080103;C0205345;C0205345;C1547039;C1547039,20/10465
nmbrth - nmbrth percentiles,C1264641,21/10465
number of ( % ) females,C0237753;C0449788,22/10465
emphysema ( % ),C0013990;C0034067,23/10465
argentina,C0003761;C1504311,24/10465
ccq score § §,,25/10465
vents / patients,C0030705,26/10465
number of patients with,C2360800,27/10465
concomitant mtx —,,28/10465
europe / lsrael,C0015176,29/10465
thromboaspiration — no . ( % ),,30/10465
cardiac - biomarker status — no . / total no . ( % ) $,,31/10465
receiving insulin therapy,C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756,32/10465
pulmonary embolism ± deep vein thrombosis,,33/10465
abdominal or perianal fistula at baseline  n ( % ),C0000726,34/10465
cyclosporine ( n = nmbr ),C0010592;C0010594,35/10465
geographic region - europe,C0017446,36/10465
indian ( indian subcontinent ),C1524069,37/10465
percutaneous coronary intervention,C1532338,38/10465
antiplatelet or anticoagulant therapy,,39/10465
lesion length  mean ( sd )  mm,C0221198;C0221198;C1546698;C1546698,40/10465
non - q wave,C1518422;C1518422,41/10465
continued thienopyridine n = nmbr subjects,C0549178,42/10465
weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0005910;C0043100;C1305866;C1705104,43/10465
left ventricular ejection fraction  % af history,C0428772;C0488728,44/10465
single - vessel disease  n ( % ),C0037179;C0087136;C0205171,45/10465
geographic region — no . ( % ),,46/10465
pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657,47/10465
bmi > nmbr kg / mnmbr ( % ),C0578022,48/10465
total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439175;C0439810;C0439810,49/10465
fatigue,C0015672;C3463815;C4050243;C4554645,50/10465
nmbr to < nmbr kg / mnmbr,C0053917;C1334884,51/10465
st - elevation mi,C0520886,52/10465
azathioprine ( n = nmbr ),C0004482,53/10465
serum uric acid ( mg / dl ),C0455272;C0700634,54/10465
baseline mean ( sd )  % [mmol / mol],C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,55/10465
cv death  ml  or stroke,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,56/10465
atenolol ( « = nmbr nmbr ),,57/10465
previous antiarrhythmic treatment — no . ( % ),,58/10465
drugs used in diabetes  n ( % ),C0013227;C3687832,59/10465
after pci,C4049621,60/10465
secukinumab,C3179547,61/10465
mean a ± sem ( % ),,62/10465
ppi but no aspirin,C0358591;C0871125;C3811894,63/10465
nmbr mg / kg ( n = nmbr ),C0053917;C1334884,64/10465
family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % ),,65/10465
trend / het . test,C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533,66/10465
cv death + hf hospitalization,C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503,67/10465
mepolizumab  nmbr mg ( n = nmbr ),C0969324,68/10465
medical therapy only ( n = nmbr ),C0418981;C0418981,69/10465
caucasian ethnicity,C0007457;C0007457;C0043157;C0043157,70/10465
crcl at baseline < nmbr ml / min,C1846718;C1846718,71/10465
elevated hscrp > nmbr mg / l  n ( % ),C0205250;C3163633,72/10465
seizure types reported during baseline  n ( % ) a,C0036572;C1959629;C4553401,73/10465
median total cholesterol  mmol / l,C0549183;C0549183;C0876920;C0876920;C2347635;C2347635;C2348144;C2348144;C2939193;C2939193,74/10465
mean ± sd bmi  kg / mnmbr,,75/10465
first mace,C0205435;C0205435;C0205435;C1279901;C1279901;C1279901,76/10465
disease duration nmbr to bnmbr years ( n = nmbr ),C0872146;C0872146,77/10465
history of amputation — no . ( % ),,78/10465
lipid - lowering medication ( % ),C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,79/10465
previous hf hospitalization  n ( % ),C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,80/10465
mean lipid values  mg / dl,C0444504;C2347634;C2348143,81/10465
prior years taking warfarin,C0332152;C2826257,82/10465
bnp  median ( iqr )  pg / ml,C0054015;C1095989;C1417808;C2982014,83/10465
hbanmbrca  % ( mmol / mol ),,84/10465
latin america hr ( nmbr % cl ),C0023122,85/10465
current atrial fibrillation or flutter on ecg,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,86/10465
invasive,C0205281;C1334278,87/10465
estimated glomerular filtration,C0750572,88/10465
pasi score ! * *,C4528685;C4528685,89/10465
amiodarone  n ( % ),C0002598,90/10465
american indian or alaska,C0002460,91/10465
pooled simvastatin factorial studies,C1709595;C2349200;C4522255,92/10465
implantable cardioverter - defibrillator,C0162589;C2825184,93/10465
varespladib ( n = nmbr ),C2713485,94/10465
acute coronary event,C0205178,95/10465
ntpro - cnp ( ng / ml ),C3889729,96/10465
useofmedical therapyathospitaldischarge,,97/10465
coenzyme qnmbr  ^g / ml #,C0009235,98/10465
dyspnoea - mmrc grade  n ( % ),C0013404;C0013404;C0013404;C1963100;C1963100;C1963100,99/10465
triglycerides — mmol / liter,,100/10465
baseline ecrcl,C0168634;C1442488,101/10465
cardiovascular history,C1880008,102/10465
with placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408,103/10465
cardiovascular medications,C0007220,104/10465
after bronchodilation,C1371299;C3537072,105/10465
mean nmbrmwd *  m ( sd ),C0444504;C2347634;C2348143,106/10465
angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C2757044,107/10465
medication taken alone or in combination,C0013227;C3244316;C4284232,108/10465
etoricoxib dose,C0972314;C0972314;C0972314,109/10465
ischemic cerebrovascular disease  n ( % ),C0475224,110/10465
bare metal stent  n ( % ),C2825200,111/10465
mean age ( years ) ( s . d . ),C0444504;C2347634;C2348143,112/10465
dasnmbr ( esr )  mean ( sd ),,113/10465
absolute  litres,C0205344,114/10465
wml load at follow - up mri,C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715,115/10465
clopidogrel ( n = nmbr  nmbr ),C0070166,116/10465
ancestry ( % ) f,,117/10465
no p - blocker intake at randomisation ( n = nmbr ),C0369773;C2603361,118/10465
valsartan / hctz  n / n ( % ),C0216784,119/10465
> nmbr oral agents,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,120/10465
total chol  mg / dl,C0439175;C0439810,121/10465
calcium channel blockers  n ( % ),C0006684;C2757014,122/10465
bsa > nmbr %  n ( % ) t,,123/10465
benralizumab nmbr mg qnmbrw ( n = nmbr ),C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078,124/10465
blood pressure  mean ( sd ) [range]  mm hg,C0005823;C1271104;C1272641,125/10465
atenolol n = nmbr,C0004147,126/10465
type of mi ( % ),C0332307;C1547052,127/10465
mtx + non - mtx,C0025677;C1417487,128/10465
concomitant corticosteroid use  n ( % ),C0521115,129/10465
estimated glomerular filtration rate ( mdrd )  ml / min / nmbr . nmbrmnmbr,C3811844,130/10465
mild impairment ( nmbr to < nmbr ),C2945599;C2945599,131/10465
years since menopause,C0439234,132/10465
major cvd /,C0205082;C0205164;C4318856;C4521762,133/10465
medical therapy ( n = nmbr ),C0418981,134/10465
no . of tnfi among non - tnfi naive,,135/10465
use of ace inhibitor,C1524063;C1524063,136/10465
haemorrhagic,C0333275,137/10465
stroke ( vs tia ),C0038454;C4554100,138/10465
detemir / insulin glargine  %,C0537270,139/10465
screening prebronchodilator fevnmbr  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,140/10465
stent plus placebo,C0038257;C0038257;C0038257,141/10465
coronary revascularization nmbr days after randomization,C0877341;C0877341,142/10465
sacubitril / valsartan,C4033631,143/10465
no . of prior bdmards,,144/10465
mean prebronchodilator fevnmbr ( sd )  % predicted,C0444504;C2347634;C2348143,145/10465
paracetamol,C0000970,146/10465
aspirin / other antiplatelet agents  n ( % ),C0004057,147/10465
randomized to receive beta carotene,C0034656;C3815594,148/10465
bsa  % *,,149/10465
erosion score,C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,150/10465
peripheral arterial disease  n ( % ),C0085096;C1704436,151/10465
primary end point  no . of events / total no . ( % ),C2986535,152/10465
lvdd ( mm ),,153/10465
draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177,154/10465
tg < nmbr  hdl > nmbr ( n = nmbr ),C0337445,155/10465
comorbidities other than diabetes,C0009488;C0009488,156/10465
toast classification of qualifying stroke,C1710306;C1710306;C4521230;C4521230,157/10465
rasagiline  nmbr mg / day,C0525678,158/10465
metabolic syndromenmbr baseline lipids  mg / dl,C0311400;C0311400;C1524026;C1524026;C2707259;C2707259,159/10465
crude analysis  n ( % ),C0002778;C0936012;C1524024,160/10465
bypass surgery,C1536078,161/10465
missing — number / n ( % ),,162/10465
cholesterol  ( . nmbr . nmbr mmol / l )  n ( % ),C0008377,163/10465
right coronary,C0225808,164/10465
health habits,C0679786,165/10465
blood pressure,C0005823;C1271104;C1272641,166/10465
homa . % b  median ( ql  qnmbr )  %,,167/10465
severity of copd  ( gold nmbr )  %,C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,168/10465
prior myocardial infarction,C0155668,169/10465
both ptca and cabg,C2936173,170/10465
major cerebrovascular,C0205082;C0205164;C4318856;C4521762,171/10465
hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr  nmbr . nmbr ),C2985465,172/10465
diastolic blood pressure ( mm hg ) medications,C0428883;C1305849,173/10465
iglar dose at randomization ( u / day ),C0178602;C0869039;C1114758,174/10465
prior cv event at randomization !,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,175/10465
mean ± sd waist circumference  cm,,176/10465
risk of bleeding,C3251812,177/10465
cv medication  % of patients,C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503,178/10465
total updrs score ( range  nmbr - nmbr ) 卞,,179/10465
atrial fibrillation  duration — no . ( % ),,180/10465
known duration of diabetes  yr,C0205309;C0205309;C0205309;C0205309,181/10465
nmbr % < hbanmbrc < = nmbr %,C0053917;C1334884,182/10465
dactylitis count,C0239161;C0239161,183/10465
previous disease :,C0205156;C1552607,184/10465
previous dmards use  n ( % ),C0205156;C1552607,185/10465
gly nmbr . nmbr gg b . i . d n / n ( % ),C1415124;C1415124;C1415124;C1415124,186/10465
previous percutaneous coronary intervention,C0205156;C1552607,187/10465
unfractionated heparin before randomisation,C0019134;C2825026,188/10465
oad plus insulin,C0021641;C1533581;C1579433;C3714501,189/10465
diabetes with target organ disease *,C0011847;C0011847;C0011849;C0011849,190/10465
unknown type,C0439673;C0439673;C3541433;C3541433;C4050014;C4050014,191/10465
beta - blocker — no . ( % ),,192/10465
cognitive functioning,C0392334;C0392335,193/10465
( % ) nmbr - nmbr,,194/10465
history of hyperlipidemia ( % ),C4695788,195/10465
evenls per nmbr  nmbr palienl - years,C0053917;C1334884,196/10465
fasting free fatty acids ( ^mol / liter ),C0015663,197/10465
treatment after admission,C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,198/10465
rarertd antocagibtcn before andorrtzafon,,199/10465
intestinal area involved  n ( % ) $,C0021853;C0021853,200/10465
ethnicity ( % ),C0015031;C0243103,201/10465
all cardiovascular,C0007226;C3887460,202/10465
smoking in the past year,C0037369;C0453996;C1881674,203/10465
diskus only  n,C1553480;C1553480,204/10465
jsn score  mean nmbr sd,C0449820;C4050231,205/10465
number omega - nmbr number placeb fatty acid,C0237753;C0237753;C0449788;C0449788,206/10465
high - intensity statin vs medium - or low - intensity statin at randomization,C4081854,207/10465
score on nih stroke scale — median ( iqr ),,208/10465
initiation of insulin,C0589507;C0589507;C0589507;C0589507;C1158830;C1158830;C1158830;C1158830;C1704686;C1704686;C1704686;C1704686,209/10465
nmbrnd > nmbr . nmbr / < nmbr . nmbr,,210/10465
cad and abi < nmbr - nmbr §,,211/10465
pioglitazone events / n ( % ),C0071097;C0071097,212/10465
acecoumarol  no . ( % ),,213/10465
cigarette users,C0677453;C1704760;C3890423,214/10465
gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),C0017654;C1424601,215/10465
bmi ( kg / mnmbr ) cardiac parameters,C0578022,216/10465
ace inhibitor or arb at last follow - up,C0003015;C4541021,217/10465
blood urea nitrogen ( mg / dl ),C0005845;C0600137,218/10465
grip strength ( kg ),C0429271;C2598165,219/10465
current smoker — no . of patients ( % ),,220/10465
one - third radius,C0205447;C0205447,221/10465
psychosocial risk factors,C0033963;C0033963;C0542298;C0542298;C1458132;C1458132,222/10465
bursitis,C0006444,223/10465
non - hdl - c in nmbr classes,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,224/10465
family history ol diabetes ?,C1313937,225/10465
age ( years ) : nmbr - < nmbr,C0001779,226/10465
digital clubbing  n ( % ),C0009080;C0149651,227/10465
death or myocardial infarction,C0011065;C1306577;C4082313;C4552775,228/10465
risk reduction  %,C1137094,229/10465
a mini - mental state examination  omega - nmbr fatty acids vs placebo,C0451306,230/10465
pain vas  nmbr - nmbr mm,C0042815,231/10465
smoking : ex - smoker,C0037369;C0453996;C1881674,232/10465
statin treatment,C0360714;C0360714;C0360714;C0360714;C0360714;C0360714;C0360714,233/10465
pre - bronchodilator fevnmbr / fvc ratio *,C2599602;C2599602,234/10465
prior stroke or transient ischemic attack,C0332152;C0332152;C2826257;C2826257,235/10465
czp nmbr mg ( n nmbr nmbr ),C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,236/10465
microvascular eye diseased,C0443258;C0443258,237/10465
extent of disease  %,C0449279;C4553144,238/10465
mean ( nmbr % ci ) difference vs saxa + dapa + met,C0444504;C2347634;C2348143,239/10465
urgent coronary revascularization,C0439609;C3272275,240/10465
caucasian simva,C0007457;C0043157,241/10465
full analysis set,C0443225;C0443225;C0443225;C0443225;C0443225;C0443225;C0443225;C0443225;C0443225,242/10465
serious ae,C0205404,243/10465
smoking history ( ever ),C1519384,244/10465
uncodable,,245/10465
no pah therapy,C0030123;C0030123;C0030123;C3203102;C3203102;C3203102;C4284467;C4284467;C4284467,246/10465
standard ( n = nmbr ),C1442989;C2828392,247/10465
patent foramen ovale,C0016522;C0344724,248/10465
laboratory values,C0022877;C3244292;C4283904,249/10465
years  mean ( sd ),C0439234,250/10465
hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr ),,251/10465
physician ' s judgment that vka,C0031831;C0804815,252/10465
calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885,253/10465
left ventricular hypertrophy ( % ),C0149721;C3484363,254/10465
randomized to aspirin use,C0034656;C0034656;C0034656;C3815594;C3815594;C3815594,255/10465
antihypertensive  antianginal  and other cardiovascular medications,C0003364;C0003364,256/10465
glp - nmbr receptor agonist ( other than study drug ),C0018301;C0018301;C1422069;C1422069;C1425391;C1425391;C1539338;C1539338;C2350813;C2350813,257/10465
primary renal endpoint or death,C2986535,258/10465
metabolic syndrome characteristics  n ( % ),C0524620,259/10465
mean duration of disease  years,C0444504;C2347634;C2348143,260/10465
other oral hypoglycemic drug ( s ),C0359086,261/10465
> nmbr additional cv risk factorsnmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,262/10465
pancolitis,C0868908,263/10465
death from any cause,C0007465,264/10465
high - density lipoprotein cholesterol  mg / l,C0023822,265/10465
diabetes mellitus status,C1317301,266/10465
fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),C0016017;C0016017;C0016017;C1305868;C1305868;C1305868,267/10465
stool frequency subscore,C0015733;C0015733;C0015733;C0015733;C0015733;C0015733;C0015733;C0183622;C0183622;C0183622;C0183622;C0183622;C0183622;C0183622,268/10465
psap - b ( ng / ml ),C1418975;C1420002;C1425004,269/10465
no use of nmbr - asa compounds,C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063,270/10465
visit nmbr ldl cholesterol strata,C0545082;C0545082;C0545082;C0545082;C1512346;C1512346;C1512346;C1512346;C2826704;C2826704;C2826704;C2826704,271/10465
endothelin nmbr ( pg / ml ),C0079284;C0079284,272/10465
normal ( egfr > nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972,273/10465
py = nmbr . nmbr ),C0030428;C3538810,274/10465
fibrinogen,C0016006;C1167394;C2587184;C3540039,275/10465
total haq  nmbr - nmbr,C0439175;C0439175;C0439810;C0439810,276/10465
mean baseline ibdq score ( sd ) § crp concentration  mg / l,,277/10465
dipyridamole,C0012582,278/10465
aspirin and other antiplatelet,C0004057,279/10465
positive,C0439178;C1446409;C1514241;C2825490;C3812269,280/10465
age [years] ( interaction : p = nmbr . nmbr ),C0001779,281/10465
decreased appetite,C0232462,282/10465
beta - blocker ( except sotalol ),C0001645,283/10465
geometric mean crp concentration ( mg / l ),C2986759;C2986759;C2986759;C2986759;C2986759;C2986759,284/10465
duration of morning,C0449238;C2926735,285/10465
hr ( enl vs lcz ) ( nmbr % cl ),,286/10465
rf positive — number ( % ),,287/10465
selected medications — no . ( % ),,288/10465
no peripheral revascularization ( n = nmbr  nmbr ),C0205100,289/10465
white / european,C0007457;C0007457;C0043157;C0043157;C0220938;C0220938,290/10465
at least nmbr flare,C0053917;C0053917;C1334884;C1334884,291/10465
time to admission  min,C3854258;C3854259,292/10465
octave sustain,,293/10465
lm bifurcation not treated,C1261082;C1261082;C1551056;C1551056,294/10465
radial access,C0442038;C0442038;C0920847;C0920847,295/10465
history of peripheral artery disease,C0683519;C0730226;C0850708;C0944983,296/10465
baseline fev  ( l ),C0168634;C1442488,297/10465
combined trials,C0205195,298/10465
negative,C0205160;C1513916;C2825415;C2825491;C3853545,299/10465
severe dysfunction,C3274777,300/10465
fasting c - peptide  ng / ml,C0015663,301/10465
aggressive ( n = nmbr ),C0001807;C0580822,302/10465
aldosterone blocker  %,C0002006,303/10465
management of event — no . ( % ),,304/10465
> nmbrmg / dl chd status,C3642216;C3642216,305/10465
serum albumin  g nmbr nmbr,C0036773;C0728877,306/10465
intraperitoneal,C0442120,307/10465
headache,C0018681;C4553197,308/10465
left main artery,C0205091;C0205091;C0205091;C0205091;C0443246;C0443246;C0443246;C0443246;C1552822;C1552822;C1552822;C1552822,309/10465
> nmbr to < nmbr egfr  ml / min / nmbr . nmbr mnmbr a,C0053917;C1334884,310/10465
established,C0443211;C1272684,311/10465
gender ( % ) male / female,C0079399;C1522384,312/10465
chondroitin sulfate ( n = nmbr ),C0008466,313/10465
unstable angina ( biomarker negative ),C0002965,314/10465
american indian or native alaskan,C0002460,315/10465
symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878,316/10465
age ( years ) [median ( nmbrth to nmbrth percentile ) ],C0001779,317/10465
formoterol nmbr gg bid,C0060657;C0060657;C0060657;C0060657,318/10465
race or ethnic group ( % ),C0034510;C1706779;C3853635,319/10465
dihydropyridine,C0012315;C0220821,320/10465
canakinumab,C2718773,321/10465
lev status  n ( % ),C0023556,322/10465
steroids § §,,323/10465
normal / mild ckd,C0205307;C0231683;C0439166;C2347086;C4553972,324/10465
number of stent = nmbr,C0237753;C0449788,325/10465
previous medications  n ( % ),C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,326/10465
nyha class nmbr - nmbr : no { n = llll ),C1882083;C1882083,327/10465
tofacitinib nmbr mg twice daily n = nmbr,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,328/10465
verapamil sr n = nmbr no . ( % ),C1527129,329/10465
no prior ml or stroke,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,330/10465
stent length per lesion  mm,C0038257;C0038257;C0038257;C0038257,331/10465
chf history,C0018802;C0018802;C0018802;C0018802;C0018802;C0018802,332/10465
anti - ccp antibody positive,C4318437,333/10465
oral medications,C0304289,334/10465
no antidiabetic drug,C0935929,335/10465
tofacitinib nmbr mg two times a day,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,336/10465
no . of nmbr - mg acetaminophen tablets / day,,337/10465
acpa positive  %,C1525410;C1525410;C1525410;C1525410;C1525410;C1706063;C1706063;C1706063;C1706063;C1706063,338/10465
timi major / minor,C4441842,339/10465
severity of airflow limitation ( gold nmbr - nmbr )  n ( % ),C0439793;C0439793;C0522510;C0522510,340/10465
pooled simva,C1709595;C2349200;C4522255,341/10465
timi risk score — no . ( % ) : t,,342/10465
baseline dyspnea index  mean total score,C1511069,343/10465
number ( % ) of patients with event,C0237753;C0449788,344/10465
atrial fibrillation onset,C0004238;C0004238;C0344434;C0344434;C1963067;C1963067,345/10465
infarct characteristics,C0021308,346/10465
caucasian simva ( „ = nmbr },,347/10465
ticagrelor nmbr mg nmbr yr km %,C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375,348/10465
galectin - nmbr ( ng / ml ),C0607430;C0607430,349/10465
hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients .,C0020261,350/10465
nmbr mg clopidogrel load,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,351/10465
intravenous dobutamine,C0348016,352/10465
family history of diabetes — no . ( % ),,353/10465
primary prevention subgroup,C0033144;C0033144,354/10465
telmisartan ( n = nmbr  nmbr ),C0248719,355/10465
ppi use ( p = nmbr - nmbrt ),C0358591;C0358591;C0358591;C0871125;C0871125;C0871125;C3811894;C3811894;C3811894,356/10465
large mi,C0549177,357/10465
never / rarely,C2003901,358/10465
medication adherence,C2364172,359/10465
no concomitant cortcosteroid use,C0521115;C0521115;C0521115,360/10465
severity of hypertensionb,C0439793;C0522510,361/10465
clopidogrel  %,C0070166,362/10465
fevnmbr percent predicted ( sd ),C0439165,363/10465
antidiabetic medication | |,C0935929,364/10465
gad positive — no . ( % ) ^,,365/10465
intravenous vasodilators ( % ),C0443081,366/10465
european trial,C0239307;C1535514,367/10465
systemic corticosteroid use,C4053960;C4053960;C4053960;C0205373,368/10465
weight  median ( interquartile range )  kg,C0005910;C0043100;C1305866;C1705104,369/10465
indacaterol nmbr ug versus placebo,C1722260;C1722260;C1722260;C1722260,370/10465
crohn ’ s disease related surgery,,371/10465
peripheral arterial disease — no . ( % ) §,,372/10465
mases ( nmbr - nmbr )  mean ( sd ),,373/10465
duration of coronary artery disease — yr,,374/10465
hbanmbrc  mean ( sd )  % [mmol / mol],,375/10465
total cholesterol ( week nmbr ),C0201950;C0543421,376/10465
at least nmbr severe flare,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,377/10465
baseline / concomitant therapies,C0168634;C1442488,378/10465
chd eze / simva ( n = nmbr],C0280604;C3542407,379/10465
heart failure criteria met,C0018801;C0018802;C4554158,380/10465
left atrial diameter,C0225860;C0225861,381/10465
pulmonary function tests  % of predicted,C0024119;C2598152,382/10465
other nsaids,C0003211,383/10465
rheumatic heart disease,C0035439,384/10465
coronary angiography and intervention,C0085532;C1548829,385/10465
time of qualifying ecg to balloon inflation ( hrs ),C0040223;C3541383,386/10465
time from symptoms to treatment,C0040223;C0040223;C3541383;C3541383,387/10465
ratio fp / sal : sal ( nmbr % ci ),C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037,388/10465
coexisting conditions — no . ( % ),,389/10465
clopidogrel  ticlopidine  or prasugrel,C0070166,390/10465
crp ( mg / dl ) < nmbr . nmbr,C3890735;C4048285,391/10465
mean ± s . d . duration of diabetes  years,,392/10465
russia / georgia ( n = nmbr ),C0035970;C0035970,393/10465
fatal and nonfatal ml,C1302234;C1705232,394/10465
hypertension ( n 二 nmbr ),,395/10465
cv event  years,C3538987;C3538987;C4048877;C4048877;C4318503;C4318503,396/10465
oxidative stress,C0242606,397/10465
age ( yrs ) < nmbr,C0001779,398/10465
no . of previous anti - tnf drugs — no . ( % ),,399/10465
< nmbr . nmbr mmol / liter apob : apoa - l ratio,C0053917;C0053917;C1334884;C1334884,400/10465
former smoker  n ( % ),C0337671,401/10465
less than nmbr %,C0439092;C0439092,402/10465
hispanic ( n = nmbr ),C0086409,403/10465
ischemic tvr,C0475224,404/10465
any albuminuria — no . ( % ),,405/10465
baseline ics use  n ( % ),C0168634;C0168634;C1442488;C1442488,406/10465
bosentan ( n = nmbr ),C0252643,407/10465
nitrates ( oral or topical ),C0028125,408/10465
left - sided disease only,C3842976,409/10465
third heart sound  n ( % ),C0232237;C0232278,410/10465
other antiarrhythmics^,C0003195,411/10465
psa duration  years,C3810537;C3810537;C3813209;C3813209,412/10465
low molecular weight ( lmw ) heparin before randomisation,C0019139;C3536766,413/10465
interval study drug to pci,C1272706;C1552654;C1552713,414/10465
atrial fibrillation / atrial flutter  %,C0155709,415/10465
anmbr + ez n = nmbr,C0206578,416/10465
initial aspirin — no . ( % ),,417/10465
symbol digit score,C0679214;C0679214;C0679214;C0679214;C1698987;C1698987;C1698987;C1698987,418/10465
time from qualifying event to randomization,C0040223;C0040223;C3541383;C3541383,419/10465
serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472,420/10465
pav  mean ( nmbr % ci ),C0058890,421/10465
events treatment ( nmbr ),C0441471;C0441471;C0441471;C0441471;C0441471;C0441471;C0441471;C3541888;C3541888;C3541888;C3541888;C3541888;C3541888;C3541888,422/10465
annt or bnnh ( nmbr % ci ),,423/10465
geographic region  %,C0017446,424/10465
drug - related teaesnmbr,C0013227;C0013227;C1254351;C1254351,425/10465
atorvastatin dose,C0286651;C0286651;C0286651,426/10465
ldl - cihdl - c  mean ( sd ),,427/10465
prior biologic therapy ( including anti - tnfs ),C0278947,428/10465
left ventricular ejection fraction within previous nmbr mo |,C0428772;C0428772;C0428772;C0428772;C0428772;C0428772;C0428772;C0428772;C0488728;C0488728;C0488728;C0488728;C0488728;C0488728;C0488728;C0488728,429/10465
cabg or pci,C0010055,430/10465
ace inhibitor monotherapy,C0003015;C4541021,431/10465
treated with cabg — no . / total no . ( % ),,432/10465
psoriatic arthritis pain],C4317006;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872,433/10465
erythrocyte sedimentation rate — mm / hr | |,,434/10465
dose of aspirin,C4696290,435/10465
p - val . ( nmbr ),C0369773;C0369773;C2603361;C2603361,436/10465
small - artery occlusion ( lacune ),C0226001;C0226001;C0226001;C0226001;C0226001;C0226001;C0700321,437/10465
atorvastatin  n ( % ),C0286651,438/10465
baseline heart rate,C0168634;C1442488,439/10465
apo b ( mg / dl ) - mean ± sd,,440/10465
peak procedural act — sec,,441/10465
extended - duration enoxaparin  n / n ( % ),C0231448;C0231449;C0439792,442/10465
total stent length,C0439175;C0439175;C0439810;C0439810,443/10465
triglycerides  median ( range ),C0041004,444/10465
efficacy,C1280519;C1707887,445/10465
non - stemi,C3537184,446/10465
mri substudy ( n = nmbr ),C0024485;C1824234;C3890166,447/10465
lv mass index ( g / mnmbr - nmbr ),C0455825;C0455825;C0455825;C0455825;C0455825,448/10465
all with coenzyme qnmbr ( n = nmbr  nmbr ),C0009235,449/10465
serum total cholesterol  mmol / l ( sd ),C0587184;C1287371,450/10465
visits nmbrenmbr,C0545082;C1512346,451/10465
week nmbr ( itt population ),C0332174;C0332174;C0439230;C0439230,452/10465
puerperium,C0034042;C0086839;C1879329,453/10465
gold group d — no . ( % ) | |,,454/10465
atv nmbr mg study protocol,C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862,455/10465
aml / val nmbr / nmbr mg,C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467,456/10465
median albumin / creatinine ratio ( g / mg ),C0549183;C0549183;C0876920;C0876920;C2347635;C2347635;C2348144;C2348144;C2939193;C2939193,457/10465
smoking ( a ),C0037369;C0453996;C1881674,458/10465
tirofiban ( n = nmbr ),C0247025,459/10465
time from acs to randomization ( median  iqr ),C0040223;C0040223;C3541383;C3541383,460/10465
smoking pack - years,C0037369;C0453996;C1881674,461/10465
serum creatinine > nmbr mmol / l  n ( % ),C0201976;C0600061,462/10465
nonaspirin antiplatelet agent,C0722138,463/10465
use of concomitant lipid - modifying therapy,C1524063,464/10465
% stenosis  as assessed by investigator,C0678234;C1261287;C2632116,465/10465
parenteral anticoagulalion before randomization,C0030547;C4522267,466/10465
lesions bnmbr / c,C0221198;C1546698,467/10465
median fasting insulin ( iqr ) — pu per milliliter,,468/10465
death or stent thrombosis,C0011065;C1306577;C4082313;C4552775,469/10465
measured at home with automated device,C0444706;C3541902,470/10465
atenolol *,C0004147,471/10465
neuropilin ( ng / ml ),C0287275,472/10465
individuals with diabetes  n = nmbr,C0027361;C0027361;C0237401;C0237401,473/10465
basal insulin analogue : insulin,C0650607;C0205112,474/10465
mean pulse pressure  mmhg ( s . d . ) “,,475/10465
oral hypoglycemic drug,C0359086,476/10465
antihypertensive treatment,C0003364;C0003364;C0003364;C0003364;C0003364;C0003364;C0003364,477/10465
patients with > nmbr exacerbations resulting in hospital admission,C0030705,478/10465
ranolazine ( n = nmbr  nmbr ),C0073633,479/10465
final timi flow grade post - ppci,C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528,480/10465
duration of disease  median,C0872146,481/10465
ace inhibitor or arb at enrollment,C0003015;C4541021,482/10465
psoriasis duration  yrs *,C0033860;C0033860,483/10465
nmbr to < nmbr . nmbr %,C0053917;C1334884,484/10465
simvastatin monotherapy ( n = nmbr  nmbr * ),C0074554,485/10465
timi major bleeding,C0205082;C0205164;C4318856;C4521762,486/10465
small - artery occlusion,C0226001;C0226001;C0226001;C0226001;C0226001;C0226001;C0700321,487/10465
left ventricular hypertrophy — no . ( % ),,488/10465
laboratory findings,C0587081,489/10465
crp  nmol / l  median ( range ),C3890735;C4048285,490/10465
bivariate frailty model ( statin users vs non - users ),C0424594;C0424594;C0424594;C0424594,491/10465
resection performed  %,C0015252;C0728940,492/10465
liraglutide nmbr . nmbr mg ls means ( n ),C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,493/10465
ada ifg,C1060325;C1060325;C3811629;C3811629,494/10465
median change  %,C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193,495/10465
sita nmbr + pio nmbr,C0053917;C0053917;C1334884;C1334884,496/10465
combined estimated gfr and albuminuria status,C0205195,497/10465
neoplasia,C0027651;C1882062,498/10465
venous graft,C0042449;C0042449;C0042449;C0348013;C0348013;C0348013,499/10465
mean age  y  median ( range ),C0444504;C2347634;C2348143,500/10465
body - mass index ( kg / mj ) previous diagnosis,C0005893;C0578022;C1305855,501/10465
antihyperglycemic,C0020616,502/10465
duration of ra ( time from symptom onset )  years,C0449238;C0449238;C0449238;C0449238;C2926735;C2926735;C2926735;C2926735,503/10465
grouped region,C0439745;C0439745;C4319846;C4319846,504/10465
nitrate — no . ( % ),,505/10465
shs  mean nmbr sd,,506/10465
oral antidiabetes monotherapya  n ( % ),C0442027;C4521986,507/10465
patients without ra  as  or psa ( n = nmbr  nmbr ),C0030705;C0030705,508/10465
treatmentofpulmonary embolismpriorto randomization,C0034656,509/10465
renin - angiotensin inhibitors,C2917241;C2917241;C3653375;C3653375,510/10465
fevnmbr  litres ( post - salbutamol )  mean ( sd ),,511/10465
upper respiratory tract infection nmbr ( nmbr . nmbr ),C0041912;C0041912,512/10465
age at diagnosis  y,C1828181;C3173302,513/10465
change in mtss ( mean ),C0392747;C0443172;C1705241;C4319952,514/10465
aliskiren ( n = nmbr ),C1120110,515/10465
number of exacerbations in last nmbr months ,C0237753;C0449788,516/10465
p  all vs all,C0369773;C2603361,517/10465
fasting plasma insulin — mu / liter,,518/10465
baseline albumin / creatinine ratio in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,519/10465
cvd risk factors ( age > nmbr ),C0007222;C0007222,520/10465
former smoker ( n = nmbr ),C0337671,521/10465
prior use of biologics  n ( % ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,522/10465
amlodipine nmbrmg / v = nmbr,C0051696;C0051696,523/10465
moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,524/10465
ethnic group — no . ( % ) ',,525/10465
any event,C0441471;C4019010,526/10465
pain in extremity,C0030196;C4553007,527/10465
hospitalized for asthma  n ( % ) *,C0701159;C0701159,528/10465
sex : male ( n = nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,529/10465
apolipoprotein b^,C0003593,530/10465
abnormal angiogram,C0205161;C0205161;C0205161;C0205161;C2347472;C2347472;C2347472;C2347472;C2699333;C2699333;C2699333;C2699333,531/10465
three or more drugs,C0205449,532/10465
data missing,C1511726;C3245479;C3714741,533/10465
heart failure nyha ii - iii,C0018801;C0018801;C0018801;C0018801;C0018802;C0018802;C0018802;C0018802;C4554158;C4554158;C4554158;C4554158,534/10465
cerebrovascular disease  n ( % ),C0007820,535/10465
western europe hr ( nmbr % cl ),C0043129,536/10465
biologic agents,C0005515,537/10465
ls mean difference ± seb,,538/10465
factor xa inhibitor,C2825027;C4553708,539/10465
mean bmi  kg / mnmbr ( s . d . ),C0444504;C2347634;C2348143,540/10465
anti - ischaemia agents *,C0040616;C0040616,541/10465
exposure,C0274281;C0332157,542/10465
mycophenolate mofetil,C0209368,543/10465
age when diabetes first diagnosed — yr,,544/10465
randomization to placebo or telmisartan,C0034656;C0034656;C0034656,545/10465
aspirin nmbr clopidogrel,C0004057;C0004057,546/10465
chd risk equivalents  n ( % ),C1282512;C1282512,547/10465
systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),C0488055;C0871470;C1306620,548/10465
clinical history,C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,549/10465
ezetimibe + simvastatin ( n = nmbr * ),C1532737,550/10465
duration of psoriasis  years,C0449238;C2926735,551/10465
procedures for index event,C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935,552/10465
killip class at admission — no . / total no . ( % ),,553/10465
other lipid parameters,C0023779,554/10465
tc / hdl - c ratio,C0039411;C0039411;C0040642;C0040642;C0041405;C0041405;C0041698;C0041698;C1824670;C1824670;C3272447;C3272447;C4522122;C4522122,555/10465
ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140,556/10465
peri - or postmenopausal,C0347985,557/10465
indeterminate or unknown,C0205258,558/10465
ratet ( nmbr % cl ),,559/10465
> nmbr % stenosis of coronary  carotid  or lower extremity arteries,C0053917;C0053917;C1334884;C1334884,560/10465
atrial fibrillation / flutter  n ( % ),C0155709,561/10465
hypertension — no . ( % ) hypercholesterolemia — no . ( % ),,562/10465
pulmonary disease,C0024115,563/10465
region of enrollment  n ( % ) +,C0017446;C0017446;C0017446;C0205147;C0205147;C0205147,564/10465
baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr,C0168634;C0168634;C1442488;C1442488,565/10465
statin + ezetimibe  n ( % ),C0360714,566/10465
ldl - c ( calculated ) *,,567/10465
evaluable for acrnmbr at week nmbr  n,C1516986,568/10465
tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,C0053917;C1334884,569/10465
ez / simva n = nmbr n ( % ),C0206578,570/10465
event rates  %,C0441471;C0441471;C4019010;C4019010,571/10465
baseline nmbr - h ppg ,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,572/10465
nontrial ppi,C0358591;C0871125;C3811894,573/10465
cardiac resynchronization therapy,C1167956,574/10465
nyha class iii or iv ( n = nmbr ),C1882086,575/10465
oral agents use,C0442027;C0442027;C0442027;C4521986;C4521986;C4521986,576/10465
recurrent ischemia - urgent revascularization,C1455761;C1455761;C1455761;C1455761;C2945760;C2945760;C2945760;C2945760,577/10465
rheumatoid factor positive §  n ( % ),,578/10465
serum pnmbrnp ( ^g / liter ),C0229671;C1546774;C1550100,579/10465
investigator - reported hypoglycaemia *,C0035173;C0035173;C0035173;C0035173;C0035173;C0035173,580/10465
diuretic — no . / total no . ( % ),,581/10465
interleukin - nmbr ( ng / l ),C0021764;C0021764;C1527200;C1527200,582/10465
non - caucasian eze / simva ( „ = nmbr },,583/10465
median ( qnmbr : qnmbr ) tgs,C0549183;C0876920;C2347635;C2348144;C2939193,584/10465
indacaterol nmbr ug versus indacaterol nmbr ug,C1722260;C1722260;C1722260;C1722260,585/10465
score of > nmbr . nmbr — %,,586/10465
weight  median ( nmbrth — nmbrth percentiles )  kg,,587/10465
nmbr - nmbr ( n = nmbr  nmbr ),C0053917;C1334884,588/10465
anti - cholinergics ( short - acting ) a,C0242896,589/10465
north america n z nmbr,C0028405;C0028405,590/10465
diabetes durationa < median,C0011847;C0011849,591/10465
discontinuations,C0457454,592/10465
available baseline blood specimen n,C0470187;C0470187,593/10465
quicki,,594/10465
ratio of women to men — %,,595/10465
randomization to arterial sheath insertion,C0034656;C0034656;C0034656;C0034656;C0034656;C0034656;C0034656;C0034656,596/10465
p value versus placebo,C1709380,597/10465
history of cardiac arrhythmia,C3494593,598/10465
n analysed,C0369718;C0441922,599/10465
body mass  kg,C0518010,600/10465
mean cdai score,C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,601/10465
placebo plus aspirin,C0032042;C1696465;C1706408,602/10465
ii - iv ( % ),C1710602;C1710602;C4082587;C4082587,603/10465
previous bowel resection performed — no . of patients ( % ),,604/10465
left anterior descending  n ( % ),C0441998;C0441998,605/10465
postmenopausal hormone use,C0232970;C0232970;C0232970;C0232970;C0232970;C0232970,606/10465
femoral neck,C0015815,607/10465
standard control ( n = nmbr ) no . of patients ( percent ),C1442989;C1442989;C1442989;C1442989;C1442989;C1442989;C2828392;C2828392;C2828392;C2828392;C2828392;C2828392,608/10465
other asian,C0078988,609/10465
measurements,C0242485,610/10465
antithrombotic / coagulant,C0009117,611/10465
myocardial infarction within the previous nmbr yr,C0027051;C0027051;C0027051;C0027051;C0428953;C0428953;C0428953;C0428953;C2926063;C2926063;C2926063;C2926063;C3810814;C3810814;C3810814;C3810814;C4552959;C4552959;C4552959;C4552959,612/10465
receiving concomitant nsaids and / or cox - nmbr inhibitors,C1514756,613/10465
b digit symbol substitution  omega - nmbr fatty acids vs placebo,C0582802;C0582802;C0582802;C0582802;C3241971;C3241971;C3241971;C3241971,614/10465
post - bronchodilator ratio of fevnmbr to fvc — %,,615/10465
statin with niacin,C0360714;C0360714,616/10465
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778,617/10465
anti - inflammatory drugs,C0003209,618/10465
i & ii : fevnmbr > nmbr % predicted,C0021966;C0221138,619/10465
interval clopidogrel to pci,C1272706;C1552654;C1552713,620/10465
procedure,C0184661;C2700391;C3274430;C3539779,621/10465
electrophysiological study — no . ( % ) weight — ibj,,622/10465
montelukast ( n = nmbr ),C0298130,623/10465
nmbr - h pmg ( mg / dl ),C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,624/10465
phenytoin,C0031507;C0202454,625/10465
enact - nmbr trial rerandomization to natalizumab ( n = nmbr ),,626/10465
nmbr bmi  kg / m,C0053917;C1334884,627/10465
baseline ldl cholesterol,C0168634;C0168634;C1442488;C1442488,628/10465
iglar ( insulin glargine lnmbr u ),,629/10465
llv wlalil nmbr statin,C0053917;C1334884,630/10465
number of prior csdmards  n ( % ),C0237753;C0237753;C0449788;C0449788,631/10465
efficacy and safety : net adverse clinical events *,C1280519;C1707887,632/10465
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778,633/10465
heart disease risk factors,C0741920,634/10465
statin use at baseline,C0360714;C0360714;C0360714;C0360714;C0360714;C0360714,635/10465
current smoker : ex - smoker ( % ),C3173209;C3241966,636/10465
aspirin but no ppi,C0004057,637/10465
nsaid use — no . / total no . ( % ),,638/10465
dx at presentation  n ( % ),C3538936,639/10465
recent surgery or trauma,C0332185;C0332185;C0332185;C0332185,640/10465
left anterior descending,C0441998;C0441998,641/10465
ezetimibe nmbr mg + statin ( n = nmbr  nmbr ),C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985,642/10465
coumadin,C0699129,643/10465
device group,C1706365,644/10465
glargine,C0907402,645/10465
safety population  n ( % ),C0036043;C0036043;C1705187;C1705187,646/10465
pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834,647/10465
all randomized patients ( range ),C0034656;C3815594,648/10465
permanent,C0205355,649/10465
tocilizumab,C1609165,650/10465
nmbr = help needed  still independent,C0053917;C1334884,651/10465
non - metsyn,C1518422,652/10465
hemoglobin  g nmbr nmbr,C0019046,653/10465
level of renal impairment,C0441889;C0456079;C1547707;C2946261,654/10465
soe or sue,,655/10465
previous stroke ortransient ischaemic attack ( % ),C0205156;C0205156;C1552607;C1552607,656/10465
clopidogrel / ticlopidine,C0070166,657/10465
selexipag,C2000145,658/10465
mi type unknown ( % ),C3810814;C3810814,659/10465
crohn ' s disease,C0010346,660/10465
high - sensitivity crp — mg / liter | |,,661/10465
prior coronary revascularization,C0332152;C2826257,662/10465
severe teaes,C0205082;C4050465;C4050466,663/10465
any statin + other llt,C0360714,664/10465
arb at last follow - up,C3888198;C3888198;C3888198;C3888198,665/10465
ml without st - segment elevation !,C0439526;C1705224;C3887665,666/10465
hydralazine,C0020223,667/10465
multivessel pci,C4049621,668/10465
oral anticoagulant — no . / total no . ( % ),,669/10465
notable abnormalities,C4288581;C4288581,670/10465
contrast nephropathy risk score,C0009924;C0009924;C0009924;C0009924;C1979874;C1979874;C1979874;C1979874,671/10465
aspirin at last follow - up,C0004057;C0004057;C0004057;C0004057,672/10465
physical component,C0031809;C0031809;C0205485;C0205485;C1509143;C1509143,673/10465
indacaterol nmbr gg qd,C1722260;C1722260;C1722260;C1722260,674/10465
elderly ( > nmbr years ),C0001792;C1999167,675/10465
odds ratio versus placebo ( nmbr % ci ),C0028873,676/10465
geographic region - north america,C0017446,677/10465
all patients with fistulas ( n = nmbr ),C0030705,678/10465
fevnmbr / fvc ( post - albuterol ),C3714541,679/10465
prior medications,C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,680/10465
location of ml,C0450429;C0450429;C0450429;C1515974;C1515974;C1515974;C4284930;C4284930;C4284930;C4284931;C4284931;C4284931,681/10465
use of hormone replacement therapy ( a ),C1524063,682/10465
versus tiotropium nmbr . nmbr pg,,683/10465
prior coronary revascularization  n ( % ),C0332152;C2826257,684/10465
duration of infusion — hr,,685/10465
beta - blocker at last follow - up |,C0001645;C0001645;C0001645;C0001645,686/10465
rentrop score,C0449820;C4050231,687/10465
randomisation visit ( baseline ),C0034656;C0034656;C0034656,688/10465
gastrointestinal area involved — no . / total no . ( % ),,689/10465
baseline pulmonary medication  n ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,690/10465
median serum periostin  ng / mla,C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193,691/10465
multiple tnfi *,C0439064,692/10465
diet + pravastatin ( n = nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949,693/10465
prior coronary artery bypass graft surgery,C0332152;C2826257,694/10465
c - peptide  median ( ql  qnmbr )  nmol / l,C0006558,695/10465
enoxaparin,C0206460,696/10465
vorapaxar placebo nmbr - yr %,C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,697/10465
missing data,C4684714,698/10465
risk reduction ( %  nmbr % ci ),C1137094,699/10465
fastest third,C0015663;C0456962;C2985769,700/10465
gemfibrozil,C0017245,701/10465
chanmbrdsnmbr - vasc,,702/10465
ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737,703/10465
( nmbr % ci] nmbr,C0053917;C0053917;C1334884;C1334884,704/10465
triglycerides mean ( mg / dl ± sd ),,705/10465
incidence rate,C1708485,706/10465
urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C1318330,707/10465
minimum stent diameter,C4054490,708/10465
nt - probnp pg / mla ( iqr ),C0669479;C0669479;C0669479;C0754710;C0754710;C0754710,709/10465
body mass index ( bmi )  kg / mnmbr,C0005893;C0578022;C1305855,710/10465
diet plus pravastatin group ( n = nmbr ),C0012155;C0012155;C0012155;C0012155;C0012155;C0012155;C0012159;C0012159;C0012159;C0012159;C0012159;C0012159;C1519433;C1519433;C1519433;C1519433;C1519433;C1519433;C2983588;C2983588;C2983588;C2983588;C2983588;C2983588;C3668949;C3668949;C3668949;C3668949;C3668949;C3668949,711/10465
duration of clopidogrel pretreatment 一 hr median,,712/10465
family history of coronary artery disease,C2317524,713/10465
sex  n ( % ) male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,714/10465
cv risk factor - no . ( % ),C3538987;C4048877;C4318503,715/10465
valvular disease ( % ),C3258293,716/10465
no corticosteroid + no imm  n,C0001617;C3536709,717/10465
antimalarials only,C0003374;C0003374,718/10465
tnl ultrapositive > nmbr . nmbr pg / l  nmbr = nmbr,C1540071,719/10465
dactylitis count ( nmbr - nmbr )  mean ( sd ),C0239161;C0239161,720/10465
nasal polyps,C0027430,721/10465
verapamil sr n = nmbr,C1527129,722/10465
continued thienopyridine n ( % ),C0549178,723/10465
disease - progression composite outcome !,C0679250;C0679250;C0679250;C0679250;C3542417;C3542417;C3542417;C3542417;C0242656;C0242656;C1335499;C1335499;C1947900;C1947900;C4552808;C4552808,724/10465
egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr  n ( % ),,725/10465
diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317,726/10465
uric acid ( mg / dl ),C0041980,727/10465
pasi score  mean ± sd,,728/10465
theophylline compound,C0039771;C0039771,729/10465
heterogeneity / trend test,C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960,730/10465
disease,C0012634,731/10465
hispanic / latin american,C0019576,732/10465
isolated pulmonary embolism,C0205409;C1548221,733/10465
middle tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),,734/10465
total cholesterol ( mg / dl )  mean + sd  available for nmbr patients,C0201950;C0543421,735/10465
geometric mean of baseline,C2986759;C2986759,736/10465
baseline fvc  l,C0168634;C1442488,737/10465
csf nmbrs - hydroxy -,C3540512;C3540512;C3889436;C3889436,738/10465
mean annualized exacerbation rate,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,739/10465
placebo no . / total ( % ),C0032042;C1696465;C1706408,740/10465
not reported / unknown,C1518422,741/10465
prior therapy with tnf antagonist  n ( % ),C1514463;C0332152;C2826257,742/10465
difference from baselinea,C1705241;C1705242,743/10465
age at randomization ( years ),C0001779,744/10465
never used lev,C2003901,745/10465
single vessel coronary artery disease *,C0581374,746/10465
non - sulfonylurea secretagogues,C1518422;C1518422,747/10465
index event asymptomatic or unconfirmed,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,748/10465
baseline medical therapy,C0168634;C1442488,749/10465
prior corticosteroid failure only,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,750/10465
one or more blood pressure medications  n ( % ),C0205447,751/10465
evomab ( n = nmbr ),,752/10465
baseline post - bronchodilator % predicted fev  < nmbr %,C0168634;C0168634;C1442488;C1442488,753/10465
cardiovascular hospitalization,C0007226;C3887460,754/10465
crohn ' s disease activity index score],C0451071;C0451071,755/10465
prior use of biologic agents,C0332152;C2826257,756/10465
relative risk reduction ( nmbr % cl ),C0242492;C0242492;C0242492;C0242492;C0080103;C0205345;C1547039,757/10465
hbanmbrc distribution,C0520511;C1704711,758/10465
diuretic agent,C0012798;C0012798;C0012798,759/10465
patients treated with insulin,C0030705,760/10465
estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,C0750572;C0750572,761/10465
nmbr - aminosalicylic compounds — no . ( % ),,762/10465
iwqol - lite physical score ( arbitrary units ),C4483112,763/10465
bdi total score ( baseline ),C0006448;C0451022;C3714938;C3889415,764/10465
estimated * creatinine clearance < nmbr mlvmin  %,C0750572,765/10465
low - density lipoprotein cholesterol  %,C0023824,766/10465
education  high school or higher,C0013621;C0013622;C0013658;C0039401,767/10465
partial mayo clinic scored,C0728938;C0728938;C0728938;C0728938;C1550516;C1550516;C1550516;C1550516,768/10465
prior lipid - modifying therapy,C1514463,769/10465
cv risk factor,C3538987;C4048877;C4318503,770/10465
mets w / o tnmbrdm,C0812270;C1705694;C2939420,771/10465
other countries,C0454664,772/10465
smoking history — no . ( % ),,773/10465
other vascular disease — no . ( % ),,774/10465
mean — g / dl,,775/10465
outcome,C1274040,776/10465
ccbs  ( % ),C0006684,777/10465
sfc nmbr / nmbr | ig bid n = nmbr,C4521536;C4521536;C4521536;C4521536;C4521536;C4521536,778/10465
cangrelor  %,C1121991,779/10465
losartan n = nmbr,C0126174,780/10465
laba + ics,C0815320;C4551720,781/10465
short - acting anticholinergics,C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002,782/10465
> nmbr vessels with > nmbr % stenosis,C0053917;C1334884,783/10465
concomitant antihyperglycaemic drugs  n ( % ),C0521115;C0521115,784/10465
losmapimod,C3272847,785/10465
history of myocardial infarction ( % ),C1275835,786/10465
nmbr - nmbr with cv disease ( n = nmbr ),C0053917;C1334884,787/10465
severely impaired,C0205082,788/10465
estimated creatinine clearance < nmbr ml / min *,C0750572,789/10465
anticyclic citrullinated peptide positive^  n ( % ),C1320283;C1320283;C1320283;C1320283;C1320283,790/10465
wrist fracture,C0435630;C4553927,791/10465
mtx exposure ( mg / week ),C0025677;C0025677;C1417487;C1417487,792/10465
ischaemic  n ( % ),C0475224,793/10465
atenolol n = nmbr no . ( % ),C0004147,794/10465
vascular disordersb,C0005847;C1558950;C1801960,795/10465
adjusted mean change from baseline ( nmbr % ci )  % [mmol / mol],C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081,796/10465
< nmbr . nmbr mmol / liter triglyceride level,C0053917;C1334884,797/10465
previous myocardial infarction — no . ( % ),,798/10465
time since diagnosis of diabetesa  n ( % ),C0040223;C3541383,799/10465
fevnmbr / fvc  %  mean ( sd ) nmbr,C3714541,800/10465
> nmbr . nmbrmmol / l ( n = nmbr ),C0053917;C1334884,801/10465
serum albumin  g / dl,C0036773;C0728877,802/10465
classification of af  no . ( % ),C0008902;C0008902;C0008903;C0008903;C0678229;C0678229,803/10465
age at screening,C0001779;C0001779;C0001779;C0001779;C0001779;C0001779;C0001779,804/10465
change in sbp ( nmbr months ),C0392747;C0443172;C1705241;C4319952,805/10465
bronchitis,C0006277,806/10465
left ventricular ef  mean ( sd )  %,C0225897,807/10465
pdenmbr inhibitor monotherapy,C1999216,808/10465
ischemic heart disease  %,C0010054;C0151744,809/10465
neither pbo + statin eze + statin,C0031962,810/10465
impaired fasting glucose level ( n = nmbr ),C1272092;C1272092;C1272092;C1272092;C0221099,811/10465
cancer ( n = nmbr ),C0006826;C0998265;C1306459,812/10465
selected clinical characteristics  n ( % ),C1707391,813/10465
lumbar spine,C0024091;C3887615,814/10465
reversibility of fevnmbr ( % ),C0449261,815/10465
missing data — no . / total no . ( % ),,816/10465
insulin ( pmol / l ) t vital signs,C0021641;C1533581;C1579433;C3714501,817/10465
glucose - lowering therapies,C0017725;C0017725,818/10465
baseline heart failure severity nyha class i,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,819/10465
selected baseline medications,C1707391;C1707391;C1707391;C1707391;C1707391;C1707391;C1707391;C1707391,820/10465
endovascular — no . ( % ),,821/10465
aspirin - erdp ( n = nmbr  nmbr ),C0004057,822/10465
previous treatment with tnf antagonist — no . ( % ) §,,823/10465
zotarolimus - eluting,C1700035,824/10465
change in nt - probnp at nmbr months ( log - transformed ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,825/10465
low - molecular - weight,C0041667;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,826/10465
heart rate ( b . p . m . )  mean ± sd,,827/10465
vorapaxar group ( n = nmbr ),C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,828/10465
glucose test,C0337438;C0595310,829/10465
number of concomitant aeds  n ( % ),C0237753;C0449788,830/10465
mean number of exacerbations ( per patient - year [nmbr % ci] ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,831/10465
use nmbr - asa compounds,C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944,832/10465
glycemic drugs,C0005802;C0005802,833/10465
balloon angioplasty — no . ( % ),,834/10465
prior history of cardiovascular disease  n ( % ),C0332152;C2826257,835/10465
accp bleeding risk at inclusion  no . ( % ) f,C3251812;C3251812,836/10465
angina pectoris — no . ( % ),,837/10465
history of systemic hypertension,C0455527,838/10465
angiography — no . ( % ),,839/10465
prasugrel,C1620287,840/10465
cardiovascular disease,C0007222,841/10465
prior congestive heart failure,C0332152;C2826257,842/10465
post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),C2599594,843/10465
diabetes therapy  n ( % ),C3274787;C3539002,844/10465
low - dose aspirin use at baseline yes,C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320,845/10465
medication at enrollment — no . ( % ),,846/10465
age  yrs  median ( nmbrth  nmbrth ),C0001779,847/10465
no . of predictors of cardiovascular risk,,848/10465
mean ( s . d . ) free pcsknmbr  ng / ml,C0444504;C2347634;C2348143,849/10465
enrollment in lmwh,C1516879;C1516879;C1696073;C1696073;C3888021;C3888021,850/10465
coronary angiography during the index hospital stay,C0085532;C0085532;C0085532;C0085532;C0085532;C1548829;C1548829;C1548829;C1548829;C1548829;C0428776,851/10465
primary pci ( n = nmbr ),C0205225;C0439612;C0439631,852/10465
versus tiotropium + olodaterol nmbr . nmbr / nmbr pg,,853/10465
long - acting or short - acting nitrates,C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317,854/10465
cardiovascular and respiratory,C0007226;C3887460,855/10465
hispanic ethnic group — no . ( % ) f,,856/10465
placebo  n ( rate ),C0032042;C1696465;C1706408,857/10465
calcium antagonists  n ( % ),C0006684,858/10465
egfr  ml / min / mnmbr,C1739039;C3811844;C3812682,859/10465
lipid lowering medication use,C0023779;C0023779,860/10465
opg  ( ng / ml ),C1262886;C1336645;C1412836;C1710303,861/10465
final timi flow,C0205088;C1546485;C3853528,862/10465
patient ' s global assessment of disease activity  mean ( sd ),C4054228,863/10465
with revascularisation,C0581603,864/10465
antihypertensive medication or,C0003364,865/10465
level nmbr immobility § | |,,866/10465
serum creatinine  limo nmbr nmbr,C0201976;C0600061,867/10465
central / eastern europe / russia,C0682369;C0205099;C1879652,868/10465
role physical,C0035820;C0035820;C0035820;C1705810;C1705810;C1705810;C3871154;C3871154;C3871154,869/10465
hbanmbrc category  n ( % ),C0683312;C3889287,870/10465
not reported in ecrf,C1518422,871/10465
beta - blockers ( all )  n ( % ),C0001645,872/10465
laba users,C1706077,873/10465
creatinine clearance at admission ( ml / min ),C0812399;C0812399,874/10465
egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr  nmbr ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,875/10465
other anticoagulant,C0003280;C0848112;C3536711,876/10465
severe impairment ( < nmbr ),C0205082;C0205082;C4050465;C4050465;C4050466;C4050466,877/10465
pre - bronchodilator fevnmbr ( % predicted normal ),C2599602,878/10465
insulin + oad,C0021641;C1533581;C1579433;C3714501,879/10465
clopidogrel ( n = nmbr ),C0070166,880/10465
first - generation stentt,C0205435;C0205435;C1279901;C1279901,881/10465
crp  mg / l : median ( range ),C3890735;C4048285,882/10465
least square mean ( se ),C0023189;C0023189;C0023189,883/10465
preoperative heart rate ( beats per minute ),C0445204,884/10465
angiography during index hospitalization,C0002978;C0002978;C0002978;C0002978;C0002978,885/10465
allhat - llt,C2347090,886/10465
prior cardiovascular event — no . ( % ) - j -,,887/10465
baseline killip class,C0168634;C1442488,888/10465
score on modified rankin scale — no . ( % ) §,,889/10465
energy / fatigue,C0424589;C0424589;C0424589;C0424589;C0542479;C0542479;C0542479;C0542479;C1442080;C1442080;C1442080;C1442080;C4330907;C4330907;C4330907;C4330907,890/10465
atrial flutter,C0004239;C0344423;C1963068,891/10465
subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811,892/10465
active a,C0205177;C3853793;C3888249,893/10465
rec . ischemia leading to hasp,C1424025;C1424025;C2606415;C2606415,894/10465
history of cabg surgery  n ( % ),C0455610,895/10465
western europe and other,C0043129,896/10465
qualifying mi type,C1514624;C1514624,897/10465
potassium - sparing at last follow - up,C0032821;C0032821;C0032821;C0032821;C0202194;C0202194;C0202194;C0202194;C0304475;C0304475;C0304475;C0304475;C0597277;C0597277;C0597277;C0597277;C3714637;C3714637;C3714637;C3714637,898/10465
congestive heart failure  n ( % ),C0018802,899/10465
score distribution : < nmbr,C0449820;C0449820;C4050231;C4050231,900/10465
candesartan nmbr / nmbr,C0717550;C0717550,901/10465
planned treatment strategy,C0599880,902/10465
/ ’ - valuenmbr ’,,903/10465
parental history of myocardial infarction before nmbr yr of age ( % ),C0030551,904/10465
hbanmbrc distribution at baseline  n ( % ),C0520511;C0520511;C1704711;C1704711,905/10465
change in haq - di ( mean ) t,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,906/10465
normoalbuminuria at baseline ( nmbr % of patients treated ),C0168634;C1442488,907/10465
previous deep - vein thrombosis or pulmonary embolism,C0205156;C1552607,908/10465
placebo mean ( n ),C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408,909/10465
previous coronary revascularization — no . ( % ),,910/10465
medical history and risk factors — no . ( % ),,911/10465
rankin grade,C0441800;C0919553;C3244287,912/10465
previous heart failure,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,913/10465
ptca or pci,C2936173,914/10465
inflammatory disease,C1290884,915/10465
exacerbations,C4086268,916/10465
statin ( open ),C0360714,917/10465
glyburide ( n = nmbr ),C0017628,918/10465
history of cardiovascular disease — no . ( % ) ^ |,,919/10465
heart failure — no . ( % ),,920/10465
normoglycemicnmbr,,921/10465
fevi  % predicted  mean ( sd ) nmbr,C0849974;C1561566;C4528367,922/10465
cardiac failure  n ( % ),C0018801;C0018802,923/10465
previous vascular disease,C0205156;C1552607,924/10465
ethnic origin  n ( % ),C0015031,925/10465
abatacept monotherapy ( n = nmbr ),C1619966,926/10465
calcium channel antagonists  n ( % ),C0006684;C2757014,927/10465
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,928/10465
ra symptom duration — year,,929/10465
previous myocardial infarction ( % ),C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607,930/10465
post - bronchodilator fvc ( l ) a,C2599594,931/10465
moderate risk,C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,932/10465
< nmbr . nmbr mm hg diastolic blood pressure,C0053917;C0053917;C1334884;C1334884,933/10465
nmbr mg cohort,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,934/10465
exercise times per week  ( minimum,C0015259;C1522704,935/10465
other ( nmbr . nmbr % ) t,,936/10465
medical conditions  no . ( % ),C0199168;C0199168;C0199168;C0199168;C0205476;C0205476;C0205476;C0205476,937/10465
smoking status at screening  n ( % ),C1519386;C1519386;C1519386;C1519386;C1519386;C1519386;C1519386;C0037369;C0453996;C1881674,938/10465
low - dose rivaroxaban + aspirin ( n / n ),C2608320,939/10465
revascularization,C0581603,940/10465
hoehn and yahr stage ( range  nmbr - nmbr ),C0205390;C1300072;C1306673,941/10465
blood leukocyte count ( nmbr cells per l ),C0023508;C0023516;C0427512,942/10465
low risk and fewer symptoms ( group a ),C3272281;C3538919,943/10465
alt and / or ast > nmbr times uln consecutive #,C1266129;C4553172,944/10465
nmbr yr km % ( n ),C0053917;C1334884,945/10465
history of symptomatic,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,946/10465
time of symptom onset to balloon inflation ( hrs ),C1320528,947/10465
statin potency stratum  n ( % ),C0360714,948/10465
no dysglycaemia or mets,C1960636,949/10465
weight $ nmbr . nmbr kg  < nmbr . nmbr kg  n,C0005910;C0005910;C0005910;C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104;C1705104;C1705104;C1705104,950/10465
race or ethnic group,C0034510;C1706779;C3853635,951/10465
moderate impairment ( nmbr to < nmbr ),C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,952/10465
ascvd including tia,C3665365,953/10465
receiving concomitant corticosteroids,C1514756,954/10465
laba + ics ( free or fixed - dose combination ),C0815320;C4551720,955/10465
fc - ldl - c  friedewald - calculated,C2983605,956/10465
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,957/10465
receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0597357,958/10465
hyperkalemia ( > nmbr . nmbr meq / l ),C0020461;C4552983,959/10465
region of enrollment  no . ( % ),C0017446;C0017446;C0017446;C0205147;C0205147;C0205147,960/10465
mean score on haq - di §,,961/10465
medications at randomization,C0013227;C0802604;C2598133;C4284232,962/10465
nmbr  nmbr / nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884,963/10465
history of cardiovascular disease,C0455539,964/10465
> nmbr yr warfarin experience,C0053917;C0053917;C1334884;C1334884,965/10465
intervention in complex lesions,C1292781,966/10465
peak creatine kinase - mb  u / l,C0444505;C0444505,967/10465
secondary ( change in total updrs score from baseline to final visit in phase nmbr ),C0027627;C0175668;C0205436,968/10465
leflunomide ( mean dose : nmbr . nmbr mg / day ),C0063041,969/10465
antithrombotic agents  n ( % ),C1704311,970/10465
leisure,C0086542,971/10465
angiotensin receptor blocker and / or ace,C0034787;C1622222,972/10465
type of treatment  n ( % ),C0455708,973/10465
pancreatic cancer,C0235974;C0346647;C2984259,974/10465
mean iglar dose ± sd ( u / day ),,975/10465
int . p *,C3272375,976/10465
hawaiian / pacific,C0337920,977/10465
aspirin at any dose,C4696290,978/10465
baseline fpg ,C0168634;C1442488,979/10465
crp ( mg / l ) : < nmbr,C3890735;C4048285,980/10465
large - artery atherosclerosis,C0226003;C0226003,981/10465
antihyperglycemic medication usage,C0020616;C0020616;C0020616,982/10465
carotid,C0741968,983/10465
western european includinq australia  israel  and south africa,C0043128;C0043128;C0239312,984/10465
low density lipoprotein cholesterol  mg / dl * *,C0023824,985/10465
blood eosinophil count ( nmbr cells per l ),C0014467;C0014467;C0005767;C0005767;C0005768;C0005768;C0229664;C0229664,986/10465
egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),C1739039;C3811844;C3812682,987/10465
placebo n = nmbr subjects,C0032042;C1696465;C1706408,988/10465
treatment with candesartan,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,989/10465
hbanmbrc nmbr - < = nmbr %,C0053917;C1334884,990/10465
eze / simva nmbr / nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,991/10465
pulmonary rales,C0034642,992/10465
loop at last follow - up,C0445022;C0445022;C0445022;C0445022,993/10465
modified rankin scale score,C2984908;C2984908;C3854213;C3854213,994/10465
qualifying event — no . ( % ),,995/10465
claudication ( fontaine class > nmbr ),C0021775;C0311395;C1456822,996/10465
steroid use at baseline  n ( % ),C0281991;C0281991,997/10465
metabolic syndrome ( > nmbr of nmbr characteristics ),C0524620,998/10465
killip class,C1881332,999/10465
respiratory medication ( % ),C0418986,1000/10465
concomitant lipid - lowering therapy  n ( % ),C0521115,1001/10465
duration of tnmbrdm,C0449238;C2926735,1002/10465
egfr  ml min nmbr nmbr . nmbr m nmbr,C1739039;C3811844;C3812682,1003/10465
smoking status ( % ),C1519386,1004/10465
bare - metal stent — no . ( % ),,1005/10465
rate / nmbr patient - years,C0871208;C0871208;C1521828;C1521828,1006/10465
> nmbr servings / wk ( n = nmbr ),C0053917;C0053917;C1334884;C1334884,1007/10465
key secondary end point : st,C4528314,1008/10465
no . of risk factors ( % ) | |,,1009/10465
prior antihypertensive medication  n ( % ),C0332152;C2826257,1010/10465
mean yearly decline,C0444504;C2347634;C2348143,1011/10465
standard therapy,C2936643,1012/10465
phosphorus  mmol nmbr nmbr,C0031705;C0080014;C3714498,1013/10465
lipid levels — mg / dl,,1014/10465
smoking habit  n ( % ),C4505437,1015/10465
open triple ( n = nmbr ),C0175566,1016/10465
no prior hf hospitalization ( n = nmbr  nmbr ),C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,1017/10465
glyburide,C0017628,1018/10465
mean ( sd ) extent of exposure  days,C0444504;C2347634;C2348143,1019/10465
triple therapy use at screening  n ( % ),C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174,1020/10465
europe nmbr ( n = nmbr ),C0015176;C0015176,1021/10465
ankle - brachial index < nmbr . nmbr — no . ( % ),,1022/10465
number of subjects,C0237753;C0237753;C0237753;C0237753;C0237753;C0449788;C0449788;C0449788;C0449788;C0449788,1023/10465
fasting insulin,C0015663;C0015663;C0015663;C0015663,1024/10465
ace - i or arb use,C1452534;C1452534;C4284014;C4284014,1025/10465
pfo closure group ( n = nmbr ),C0185003;C0185003;C0185003;C0185003;C0185003;C0185003;C1521802;C1521802;C1521802;C1521802;C1521802;C1521802,1026/10465
median ( qnmbr : qnmbr ) duration of insulin use  years,C0549183;C0876920;C2347635;C2348144;C2939193,1027/10465
control group ( n = nmbr ),C0009932,1028/10465
normal troponin,C0205307;C0231683;C0439166;C2347086;C4553972,1029/10465
ind / glynmbr / nmbr pg o . d . n = nmbr,C4049864;C4049864,1030/10465
traditional chinese medicine for respiratory disease — no . ( % ),,1031/10465
baseline copd exacerbation history  * n ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,1032/10465
european union,C0015179,1033/10465
blood pressure - lowering treatment,C0596197;C0596197;C0596197;C0596197;C0596197;C0596197;C0596197;C0596197;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641,1034/10465
ezetimibe,C1142985,1035/10465
fish oil,C0016157,1036/10465
cardiovascular inclusion criteriat,C0007226;C0007226;C3887460;C3887460,1037/10465
median duration of study - drug administration,C0549183;C0876920;C2347635;C2348144;C2939193,1038/10465
psoriasis body surface area > nmbr %,C0033860,1039/10465
exenatide,C0167117,1040/10465
cardiovascular risk factors — no . / total no . ( % ),,1041/10465
( nmbr % ci ) p value,C0053917;C0053917;C1334884;C1334884,1042/10465
time from symptom onset to randomization,C0040223;C3541383;C1457887;C3854129,1043/10465
percentage difference ( nmbr % cl ),C0439165;C0439165;C1549488;C1549488;C1561533;C1561533,1044/10465
fpg ( mmol / l )  mean ( sd ) 、,,1045/10465
apo anmbr ( g / l ),,1046/10465
fibrinolysis ( n = nmbr ),C0016017;C1305868,1047/10465
ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375,1048/10465
combined n = nmbr,C0205195,1049/10465
simplified disease activity index,C3869582,1050/10465
ratio of ldl to hdl,C0456603;C1547037,1051/10465
st ( arc definite only ),C0036056;C0036056;C0036056;C0036056;C3272372;C3272372;C3272372;C3272372,1052/10465
duration of diabetes mellitus  y,C0449238;C2926735,1053/10465
sex  male / female  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,1054/10465
total study population ( n = nmbr  nmbr ),C3258257;C3258257;C0439175;C0439810,1055/10465
sita / pio nmbr / nmbr,C0030800;C0030800;C2347712;C2347712,1056/10465
blood eosinophils count,C0014467,1057/10465
who / idf ifg,C1334085;C1708411,1058/10465
cardiovascular history 一 no . ( % ),,1059/10465
ace inhibitor at last follow - up,C0003015;C0003015;C0003015;C0003015;C4541021;C4541021;C4541021;C4541021,1060/10465
prior cardiac surgery  n ( % ),C0455610;C0455610;C0332152;C0332152;C2826257;C2826257,1061/10465
ischemic aetiology  n ( % ),C0475224;C0475224;C0475224,1062/10465
placebo nmbr year km ( % ),C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408,1063/10465
vorapaxar n = nmbr,C2974521,1064/10465
postmenopausal  never or past hormone therapy use,C0232970,1065/10465
difference vs placebo  % [nmbr % cl]  p,C1705241;C1705242,1066/10465
urinary albumin - to - creatinine ratio^,C0455271;C1318330,1067/10465
percent change,C0439165;C0439165;C0439165;C0439165,1068/10465
standard care ( n = nmbr ),C1442989;C2828392,1069/10465
cerebrovascular disorders  n ( % ),C0007820,1070/10465
ace inhibitor — no . ( % ),,1071/10465
location of treatment center,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,1072/10465
indacaterol nmbr ug ( n = nmbr ),C1722260;C1722260;C1722260;C1722260,1073/10465
history of peripheral arterial disease ( % ),C0683519;C0683519;C0730226;C0730226;C0850708;C0850708;C0944983;C0944983,1074/10465
creatinine  mean ( sd )  mg / dl,C0010294;C1561535,1075/10465
sfnmbr - pcs,C1864389;C1882368,1076/10465
randomization groups nmbr and nmbr,C0034656,1077/10465
presence of honeycombing  nmbr n ( % ),C0150312;C0150312;C0392148;C0392148;C3854307;C3854307,1078/10465
very severe n z nmbr,C3641272;C3641272;C4050419;C4050419,1079/10465
years since pah diagnosis,C0439234,1080/10465
partial mayo score $ | |,C0728938;C0728938;C0728938;C0728938;C1550516;C1550516;C1550516;C1550516,1081/10465
rosuvastain + fenofibric acid nmbr = nmbr,C0060179;C0060179,1082/10465
severity n ( % ),C0439793;C0522510,1083/10465
history of hypercholesterolemia,C1533076,1084/10465
> nmbr years education,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,1085/10465
angiographic complications  site - reported — no . / total no . ( % ),,1086/10465
acute coronary syndrome nmbr,C0948089;C0948089,1087/10465
asastoppedat randomization  n,C0034656,1088/10465
mean blood pressure  mmhg ( s . d . j,C0428886;C0488053,1089/10465
baseline lipids  mean ± sd ( mmol / l ),,1090/10465
philippines,C0031529,1091/10465
active cancer at randomization  n ( % ),C0205177;C0205177;C0205177;C3853793;C3853793;C3853793;C3888249;C3888249;C3888249,1092/10465
current (  nmbr cigs / day ),C0521116;C1705970,1093/10465
aspirin and ppi,C0004057,1094/10465
screening % reversibility fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,1095/10465
prior pci or cabg surgery,C0332152;C2826257,1096/10465
lower - limb arterial — no . ( % ),,1097/10465
baseline disease and quality - of - life scores,C0168634;C1442488,1098/10465
index event  %,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,1099/10465
endoscopy subscore,C0014245,1100/10465
intended clopidogrel dose nmbr mg,C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357,1101/10465
placebo + mtx,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,1102/10465
celecoxib ( n = nmbr ),C0538927,1103/10465
oral hypoglycemic agent,C0359086,1104/10465
death  mi  idr  or st,C0011065;C1306577;C4082313;C4552775,1105/10465
unacceptable adverse events,C1883420;C1883420,1106/10465
tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424,1107/10465
median ( days ),C0549183;C0876920;C2347635;C2348144;C2939193,1108/10465
ldl particle size ( week nmbr ),C3641256,1109/10465
gold nmbr groups,C0018026;C0018026;C1304897;C1304897,1110/10465
parameter,C0549193;C1704769;C2350001,1111/10465
vascular intervention,C0005847;C0005847;C0005847;C1558950;C1558950;C1558950;C1801960;C1801960;C1801960,1112/10465
anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr ),,1113/10465
amlodipine / vaisartan ( n = nmbr ),C0051696,1114/10465
ldl cholesterol — mg / dl | |,,1115/10465
week nmbr ( geometric mean  cv ),C0332174;C0332174;C0439230;C0439230,1116/10465
triglycerides ( week nmbr ) a,C0041004,1117/10465
cause of heart failure,C0015127;C0015127;C0015127;C1524003;C1524003;C1524003,1118/10465
copd or asthma,C0024117;C1412502;C3714496,1119/10465
latin and north america,,1120/10465
comorbid diseasesa diabetesb,C0009488,1121/10465
cardiac rhythm,C0232187,1122/10465
proactive intervention ( n = nmbra ),C0184661;C0886296;C1273869,1123/10465
nmbr = minor symptoms  no limitations,C0053917;C1334884,1124/10465
patients ' characteristics age ( years )  mean + sd,C4698447;C0815172,1125/10465
history of hypercholesterolemia  n ( % ),C1533076,1126/10465
acc / aha lesion class bnmbr or c  n ( % ),C4072694;C4072694;C4072694;C4072694;C4072694;C4072694,1127/10465
enact - nmbr trial,,1128/10465
fasting insulin — / tiu / ml §,,1129/10465
biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl )  na,C0005516,1130/10465
age  mean years  [sd],C0001779,1131/10465
lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C1096202;C1439335,1132/10465
any pulmonary medication,C0024109;C0024109;C0024109;C2707265;C2707265;C2707265;C2709248;C2709248;C2709248;C4522268;C4522268;C4522268,1133/10465
non - study ppi use,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,1134/10465
> nmbr : obese class iii,C0053917;C1334884,1135/10465
acute dvt study,C0205178;C0205178;C0205178;C0205178;C0205178;C0205178,1136/10465
high subgroup,C0205250;C0205250;C1299351;C1299351;C2700149;C2700149;C3887512;C3887512;C3889660;C3889660;C4321237;C4321237;C4522209;C4522209,1137/10465
mean ( sd ) body mass index  kg / mnmbr,C0444504;C2347634;C2348143,1138/10465
diuretic drugs,C0012798;C0012798,1139/10465
gallbladder - related aes,C0016976;C0016976;C0016976;C0016976,1140/10465
rivastigmine ( n = nmbr ),C0649350,1141/10465
vitamin e,C0042874;C3714803,1142/10465
jvp > nmbrcm,,1143/10465
family history of venous thromboembolism ( % ),C0241889;C0015576;C0015576;C1704727;C1704727,1144/10465
post - bronchodilator fevnmbr ( % predicted * ),C2599594,1145/10465
creatinine clearance by c - g ( ml / min ),C0439267,1146/10465
associated with hiv infection,C0332281,1147/10465
muscle spasms,C0037763,1148/10465
copd severity ( gold stage ),C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,1149/10465
rivaroxaban nmbr mg,C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768,1150/10465
baseline cardiac biomarkers elevated,C0168634;C0168634;C1442488;C1442488,1151/10465
mental component score ( mcs ),C0229992;C0229992;C0229992;C0229992,1152/10465
combined end points,C0205195,1153/10465
death  large mi,C0011065;C1306577;C4082313;C4552775,1154/10465
race  white  n ( % ),C0034510;C1706779;C3853635,1155/10465
elevated tg,C0205250;C3163633,1156/10465
baseline scales  median ( range ),C0168634;C0168634;C1442488;C1442488,1157/10465
formal education  years,C0681344,1158/10465
tiotropium nmbr gg qd,C0213771;C0213771;C0213771;C0213771,1159/10465
thrombocytopenia,C0040034;C0392386,1160/10465
presence of mets,C0150312;C0150312;C0150312;C0392148;C0392148;C0392148;C3854307;C3854307;C3854307,1161/10465
treatment at randomization — no . ( % ),,1162/10465
other biologic agent,C0005515,1163/10465
hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,C3715113,1164/10465
baseline systolic bp,C0168634;C1442488,1165/10465
angina class iii or iv prior myocardial infarction,C0264677,1166/10465
mucolytic agent,C0026698,1167/10465
acenocoumaroi,,1168/10465
multiple,C0439064,1169/10465
emotional well - being,C2984554;C3641833,1170/10465
nmbr ( fevnmbr < nmbr % pred ),C0053917;C1334884,1171/10465
rec . ischemia due worsening angina,C1424025;C1424025;C1424025;C1424025;C2606415;C2606415;C2606415;C2606415,1172/10465
current ( nmbr + cigs / day ),C0521116;C1705970,1173/10465
prior surgery : no,C0455610,1174/10465
carotid stenosis,C0007282,1175/10465
smoking history  pack - years  mean ( sd ),C1519384,1176/10465
ever smoked ( current / former ),,1177/10465
estimated gfr  ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a,C0750572;C0750572,1178/10465
isolated systolic hypertension  n ( % ) “,,1179/10465
feno placebo ( lsm ),C0032042;C1696465;C1706408,1180/10465
no . of prior tnfi,,1181/10465
non - fatal myocardial infarction,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,1182/10465
involved intestinal area  n ( % ),C1879646,1183/10465
normal fasting glucose level ( n = nmbr ),C0522082;C0205307;C0231683;C0439166;C2347086;C4553972,1184/10465
saxa + dapa + met n = nmbr,,1185/10465
joint damage outcomes ( mitt population ),C0022417;C0022417;C0392905;C0392905;C1706309;C1706309,1186/10465
discontinuations teaes,C0457454,1187/10465
aldosterone inhibitor,C0002007,1188/10465
adverse outcome,C1274040,1189/10465
etoricoxib nmbr mg n = nmbr n ( % ),C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314,1190/10465
asia - pacific hr ( nmbr % cl ),C0003980,1191/10465
left bundle - branch block,C0023211;C0344420;C2828132,1192/10465
any prior anti - tnf treatment failure,C1514463;C1514463;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,1193/10465
pioglitazone pts / n ( % ),C0071097;C0071097,1194/10465
central / eastern europe and russia hr ( nmbr % cl ),C0682369;C0205099;C1879652,1195/10465
copd - rosuvastatin ( n = nmbr ),C0024117;C1412502;C3714496,1196/10465
abatacept / open - label abatacept,C1619966,1197/10465
nonblack race — no . ( % ) - j -,,1198/10465
prior ischemic stroke,C0332152;C2826257,1199/10465
ff / vi nmbr / nmbr gg ( n = nmbr  nmbr ),C4554348;C4554348;C4554348;C4554348,1200/10465
baseline nihss score ( % ) #,C0168634;C0168634;C1442488;C1442488,1201/10465
free fatty acids ( mmol / l ),C0015688,1202/10465
laba or lama ’ versus ind / gly lsm difference ( nmbr % cl ),,1203/10465
change from baseline in hbanmbrc ( % ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,1204/10465
aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,1205/10465
angiogenin ( ng / ml ),C0051844;C1367482,1206/10465
weight  mean ± sd ( kg ),,1207/10465
race / ethnicity  %,C0034510;C0034510;C1706779;C1706779;C3853635;C3853635,1208/10465
etanercept ( n = nmbr ),C0717758,1209/10465
serum creatinine — pmol / liter,,1210/10465
prior carotid intervention,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,1211/10465
abx - facil . pci,C4049621,1212/10465
antiplatelet — no . / total no . ( % ),,1213/10465
other lipid - modifying drug use at study entry  n ( % ),C0023779;C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,1214/10465
without dm ( n = nmbrinmbr * ),C0011816;C3250443,1215/10465
potassium,C0032821;C0202194;C0304475;C0597277;C3714637,1216/10465
difference ( tiotropium - placebo ) ml ( nmbr % ci ),C1705241;C1705242,1217/10465
any relevant infarct,C2347946,1218/10465
baricitinib  nmbr mg daily ( n = nmbr ),C4044947,1219/10465
ls mean % change from baseline _ se,C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,1220/10465
established ascvd or > nmbr cv risk factors,C0443211;C1272684,1221/10465
fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0015663,1222/10465
enmbr + anmbr -,,1223/10465
filtration rate nmbr - nmbr,C0016107;C0016107;C0016107;C0016107,1224/10465
placebo secukinumab nmbr mg,C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,1225/10465
sf - nmbr physical component summaryjj,C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712,1226/10465
angiographic data,C0002978;C0002978;C0002978,1227/10465
community hospital ( % ),C0020003,1228/10465
death or absolute fvc decrease > nmbr %,C0011065;C1306577;C4082313;C4552775,1229/10465
indacaterol nmbr mg[n z nmbr],C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,1230/10465
other statin,C0360714,1231/10465
median ( iqr ) age  years,C0549183;C0876920;C2347635;C2348144;C2939193,1232/10465
estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §,,1233/10465
homa_ % b tx difference vs pbo  median change from baseline ( se ) nmbr,C0041403;C0041403,1234/10465
tim nmbr nsk score,C1313407;C1313407;C1313407;C1313407;C3541335;C3541335;C3541335;C3541335;C3711667;C3711667;C3711667;C3711667;C3827754;C3827754;C3827754;C3827754;C3890185;C3890185;C3890185;C3890185;C4319633;C4319633;C4319633;C4319633,1235/10465
indication for pci,C0392360;C3146298,1236/10465
percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338,1237/10465
nmbr - aminosalicylates ’ i  i ‘,,1238/10465
native latin,C0302891,1239/10465
left atrial diameter  mm ( sd ),C0225860;C0225861,1240/10465
patient history of disease,C0030705;C0030705;C0030705;C0030705,1241/10465
copd severity : severe / very severe,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,1242/10465
mean platelet volume  fl,C0200665;C0344388,1243/10465
in ibdq total score at week nmbr  mean [se],C2964552;C2964552;C2964552;C2964552,1244/10465
baseline ezetimibe usec,C0168634;C1442488,1245/10465
ics use at screening  n ( % ),C0815320;C4551720,1246/10465
mdi / hfa  n,C0993596;C1839839;C4049613,1247/10465
moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,1248/10465
mixed chronic bronchitis and emphysema,C0205430;C3160715,1249/10465
triple - vessel disease  n ( % ),C0856738,1250/10465
mean ( sd ) crp  mg / l *,C0444504;C2347634;C2348143,1251/10465
epa / aa ratio,C0282379;C0282379;C1235746;C1235746;C1882141;C1882141;C4554792;C4554792,1252/10465
one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr,,1253/10465
health state index score  uk algorithm,C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314,1254/10465
time from onset of pain to randomization  median ( iqr )  h,C0449244;C0449244;C0449244;C0449244;C0449244;C0449244;C0449244;C0449244;C0449244,1255/10465
homajr tx difference vs pbo  median change from baseline ( se ) nmbr lipid parameters,C0041403;C0041403,1256/10465
ticagrelor  nmbr mg ( n = nmbr ),C1999375,1257/10465
dpp - nmbr inhibitor therapy,C1414174;C1414174;C1414174;C1414174;C1414174;C1414174,1258/10465
median cardiac troponin t ( iqr ) — pg / ml,,1259/10465
> nmbr ( ml ) additional angiography,C0053917;C1334884,1260/10465
sbp < nmbr mmhg and dbp < nmbr mmhg,C0085805,1261/10465
insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501,1262/10465
other antiplatelet,,1263/10465
use of ics,C1524063;C1524063,1264/10465
mean hscrp  mg / l ( sd ),C0444504;C2347634;C2348143,1265/10465
carotid revascularization,C0741968,1266/10465
time from onset to randomization  h  mean ± sd,,1267/10465
beta - adrenergic blocker,C0001645;C2757061;C3536830,1268/10465
class l / ll heart failure,C0456387;C1518526;C1705943,1269/10465
rerandomization to placebo ( n = nmbr ) f,C0032042;C1696465;C1706408,1270/10465
triglycerides > nmbr mg / dl,C0041004,1271/10465
history of cabg surgery,C0455610,1272/10465
vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769,1273/10465
thoracic cage fractures,C0222762,1274/10465
baseline sgrq score,C0168634;C1442488,1275/10465
usa and canada,C0041703,1276/10465
obesity ( body mass index > nmbr kg / mnmbr ),C0028754;C1963185,1277/10465
clopidogrel plus aspirin ( n = nmbr ),C0070166,1278/10465
intent of early invasive strategy  %,C0162425;C0162425;C1283828;C1283828;C1550453;C1550453,1279/10465
mean fevnmbr  l ( sd ),C0444504;C2347634;C2348143,1280/10465
heavy calcification,C0439539;C0439539;C0439539;C0439539;C0439539;C0439539,1281/10465
cardiovascular medications  %,C0007220,1282/10465
only peripheral artery disease,C0205171;C0205171;C1720467;C1720467,1283/10465
inhaled anticholinergic §,,1284/10465
nmbr - h plasma glucose during ogtt ( mmol / l ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,1285/10465
uacra  mg / g  n ( % ),,1286/10465
western europe and israel,C0043129,1287/10465
sglt - nmbr inhibitors^,C3665045;C3665045,1288/10465
myocardial infarction — no . ( % ),,1289/10465
united states,C0041703,1290/10465
number of antidiabetes drugs at screening  n ( % ),C0237753;C0237753;C0449788;C0449788,1291/10465
any type  according to daily dose * *,C0332307;C1547052,1292/10465
glucocorticoids plus immunosuppressive agents,C0017710;C3540777;C3540778,1293/10465
left anterior descending artery  n ( % ),C0226032,1294/10465
albuterol reversibility  %,C0001927,1295/10465
rivaroxaban + aspirin,C1739768,1296/10465
anyantianginal agent,C0450442;C1254351;C1521826,1297/10465
patients with diabetic nephropathy,C0030705;C0030705,1298/10465
hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se ),C0030705,1299/10465
health - related quality of life,C4279947,1300/10465
risk factors  %,C0035648;C1553898,1301/10465
concomitant therapy  no . ( % ),C1707479,1302/10465
any cardiovascular disease history  n ( % ),C1880008;C0007222;C0007222;C0007222;C0007222;C0007222;C0007222;C0007226;C3887460,1303/10465
cardiac history  %,C0018787;C0018787;C0018787;C0018787;C0018787;C0018787;C1522601;C1522601;C1522601;C1522601;C1522601;C1522601,1304/10465
subgroup by treatment interaction p - value,C1079230;C1079230;C1079230;C1079230;C1079230;C1079230;C1079230;C1515021;C1515021;C1515021;C1515021;C1515021;C1515021;C1515021,1305/10465
anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ),,1306/10465
dpi ( other than diskus )  n,,1307/10465
previous copd treatment  n ( % ) *,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,1308/10465
body mass index ( kg / mnmbr ) - mean ± sd,,1309/10465
positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,,1310/10465
psoriasis duration  mean ± sd  years,,1311/10465
fevi  l *,C0849974;C1561566;C4528367,1312/10465
ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0023824;C0202117;C0202117,1313/10465
black race,C0005680,1314/10465
lp ( a )  mean ( sd ),C0065058;C1439335;C4553379,1315/10465
previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,1316/10465
calculated ldl - c in nmbr classes,C0444686;C0444686;C0444686;C0444686;C0444686;C0444686;C0444686;C0444686;C1441506;C1441506;C1441506;C1441506;C1441506;C1441506;C1441506;C1441506,1317/10465
rosiglitazone,C0289313,1318/10465
without revascularsation,,1319/10465
odds ratio,C0028873,1320/10465
body mass index  kg / mnmbr  median ( qnmbr  qnmbr ),C0005893;C0578022;C1305855,1321/10465
exenatide n = nmbr,C0167117,1322/10465
total score on the sgrq - c  i ,C2964552,1323/10465
elevated creatinine ( > nmbr pmol / l ),C0151578;C0700225,1324/10465
valsartan / hctz,C0216784,1325/10465
baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,C0168634;C1442488,1326/10465
history of currently treated hypertension  n ( % ),C0455527,1327/10465
tg  mmol / l [mg / dl],C0337445,1328/10465
terminal ileum,C0227327,1329/10465
dasnmbr - esr lda,C3811131,1330/10465
prior tnfi  n ( % ),C0332152;C2826257,1331/10465
liraglutide nmbr . nmbr mg / day ( n = nmbr ),C1456408;C1456408,1332/10465
established ascvd,C0443211;C1272684,1333/10465
depressed and low perceived social support,C0344315;C0549249,1334/10465
limb ( sd ),C0015385,1335/10465
emergent / urgent surgery,C0750573,1336/10465
laboratory measurements,C0681902,1337/10465
simva n = nmbr n ( % ),,1338/10465
czp nmbr mg  % ( n / n ),C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,1339/10465
fibrinogen ( pmol / l ) c,C0016006;C1167394;C2587184;C3540039,1340/10465
frailty status,C0424594,1341/10465
basal insulin dose at run - in ( u / day ),C0650607;C0650607;C0650607;C0205112,1342/10465
worsening angina,C0002965,1343/10465
use of parenteral antithrombotic,C1524063;C1524063,1344/10465
cvd or mi,C0007222,1345/10465
screening bmi ( kg / mnmbr ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,1346/10465
atherosclerosis^  n ( % ),C0003850;C0004153,1347/10465
none ( cdmard - naive or past use at baseline ),,1348/10465
tender joint count ( nmbr - nmbr ),C0451530,1349/10465
hbanmbrc  %  n ( % ) b,,1350/10465
ldl - c < nmbr . nmbr mmol / l,,1351/10465
duration of last qualifying episode of atrial fibrillation > nmbr days,C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,1352/10465
saxagliptin nmbr . nmbr mg ( n = nmbr  nmbr ),C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,1353/10465
years [range],C0439234,1354/10465
potassium - sparing at enrollment,C0032821;C0032821;C0032821;C0202194;C0202194;C0202194;C0304475;C0304475;C0304475;C0597277;C0597277;C0597277;C3714637;C3714637;C3714637,1355/10465
body mass index > nmbr kg / mnmbr  n ( % ),C0005893;C0578022;C1305855,1356/10465
modmy al randcnxzaton,C0202311,1357/10465
additional investigations,C2359834,1358/10465
peri - op amiodarone : no ( n = nmbr ),C0347985,1359/10465
ejection fraction  % nyha class  n ( % ),C0489482;C2700378,1360/10465
class i or iii aad use in nmbr months before enrollment,C0441885;C1319793;C2698967,1361/10465
intravenous anticoagulant during hospitalization,C0348016;C0348016;C0348016,1362/10465
high density lipoprotein cholesterol  mg / dl^,C0023822,1363/10465
functional assessment of chronic illness,C0278372,1364/10465
hormonal status,C0458083,1365/10465
postmenopausal  current hormone,C0232970;C0232970;C0232970;C0232970,1366/10465
spironolactone ( n = nmbr ),C0037982,1367/10465
any disease,C0012634,1368/10465
endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875,1369/10465
bolus administered — no . ( % ),,1370/10465
tofacitinib  nmbr mg ( n = nmbr ),C2930696,1371/10465
medical history — no . / total no . ( % ),,1372/10465
tobacco use ( % ),C0040335;C0543414;C0841002;C3853727,1373/10465
infliximab - naive ( n = nmbr ),C0666743,1374/10465
week nmbr mean 士 sd,,1375/10465
hr ( nmbr % ci ) p value for interaction *,,1376/10465
history of congestive heart failure,C0455531,1377/10465
events  no .,C0441471;C3541888,1378/10465
event / total,C0441471;C0441471;C4019010;C4019010,1379/10465
serum cholesterol — mmol / liter,,1380/10465
pooled empagliflozin ( n = nmbr ),C1709595;C2349200;C4522255,1381/10465
statin monotherapy,C0360714,1382/10465
total comparators  patients with events / total patients,C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,1383/10465
( % ) control ( nmbr ),,1384/10465
hypertension : no ( n = nmbr ),C0020538;C1963138,1385/10465
angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021,1386/10465
bdmard - ir,C0022065;C0022071;C1448132,1387/10465
estimated glomerular filtration rate,C3811844,1388/10465
periprocedural medications — no . / total no . ( % ),,1389/10465
proportion of predicted normal fevnmbr value   §,,1390/10465
mellitus,,1391/10465
amiodarone,C0002598,1392/10465
permanently stopped study drug because of adverse events,C1272691;C1272691,1393/10465
median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,C0549183;C0876920;C2347635;C2348144;C2939193,1394/10465
apolipoproiein anmbr ( tng / nmbr ),,1395/10465
metformin dose  mg,C0025598;C0025598;C0025598,1396/10465
placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408,1397/10465
hbanmbrc nmbr % - < nmbr % ( n - nmbr ),C0053917;C1334884,1398/10465
hypoglycaemic agents,C0020616,1399/10465
apremilast nmbr mg bid n = nmbr,C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805,1400/10465
duration  mean ( sd )  years,C0449238;C2926735,1401/10465
patient global assessment of disease activity ( vas nmbr - nmbr mm ),C4054228,1402/10465
intermittent claudication,C0021775,1403/10465
myocardial ischaemia,C0010054;C0151744,1404/10465
arb at enrollment,C3888198;C3888198;C3888198,1405/10465
rosuvastatin of patients ( rate ),C0965129,1406/10465
recent cardioversion ( within nmbr days before randomization ) —,,1407/10465
denosumab ( n = nmbr ),C1690432,1408/10465
genotyping,C1285573,1409/10465
remission  n ( % ),C0544452;C0687702,1410/10465
radius fracture,C0034628,1411/10465
clopidogrel dose on / before pci,C0070166;C0070166;C0070166,1412/10465
enoxaparin / vka,C0206460,1413/10465
sf - nmbr score,C0037712;C0037712;C0037712;C0037712,1414/10465
seropositivity,C0521143,1415/10465
interval pain onset to admission,C1272706;C1272706;C1552654;C1552654;C1552713;C1552713,1416/10465
metrex modified intention - to - treat population with an eosinophilic phenotypey,,1417/10465
number of previous anti - tnf treatments for psoriatic arthritis,C0237753;C0237753;C0449788;C0449788,1418/10465
serum creatinine  mean ( sd )  pmol / l,C0201976;C0600061,1419/10465
coronary heart disease ( % ),C0010054;C0010068;C1956346,1420/10465
bmi ( kg / mnmbr ) < nmbr,C0578022,1421/10465
abdominal aortic — no . ( % ),,1422/10465
mean weight  kg ( sd ),C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,1423/10465
severe hyperkalemiac,C0205082;C4050465;C4050466,1424/10465
history of bone disease ( predefined )  n ( % ),C0683519;C0730226;C0850708;C0944983;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,1425/10465
abrupt vessel closure,C1276802;C1276802,1426/10465
/ j - valuc ! l,,1427/10465
> nmbr days warfarin,C0053917;C1334884,1428/10465
non - hdl - c ( mmol / l  mean ),C1518422,1429/10465
yes  non - insulin - treated,C1549445;C1705108;C1710701,1430/10465
nmbr - nmbr . nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,1431/10465
baseline lp ( a ) in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,1432/10465
primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631,1433/10465
dyspepsia,C0013395;C4552968,1434/10465
south asian,C1519427,1435/10465
claudication,C0021775;C0311395;C1456822,1436/10465
anticoagulant therapy,C0150457,1437/10465
dactylitis  n ( % ),C0239161,1438/10465
prior immunnosupressive failure but no anti - tnf failure,C0332152;C0332152;C2826257;C2826257,1439/10465
sf - nmbrvnmbr domain scores  mean [sd],C0037712;C0037712;C0037712,1440/10465
reversibility ( bnmbr - agonist )  %  mean ( sd ) nmbr,C0449261,1441/10465
icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0021122;C0021122;C0021122,1442/10465
fev  at baseline,C3714541,1443/10465
low - density lipoprotein cholesterol  mg / dl,C0023824,1444/10465
qualifying type of atherosclerosis — no . ( % ),,1445/10465
white : black : other,C0007457;C0043157;C0220938,1446/10465
placebo estimated mean,C0032042;C1696465;C1706408,1447/10465
salmeterol - fluticasone group,C0939232;C0939232;C0939232;C0939232;C0939232;C0939232,1448/10465
impaired glucose tolerance or impaired fasting glucose — no . ( % ),,1449/10465
duration of tnmbrdm ( % ),C0449238;C2926735,1450/10465
therapy ( asa nmbr  nmbr / placebo nmbr ),C0039798;C0087111;C1363945,1451/10465
antihyperglycemic oral agent therapy,C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616,1452/10465
gender  % of patients,C0079399;C1522384,1453/10465
planned thienopyridine at baseline,C1301732;C1301732,1454/10465
medical history,C0262926;C1704706,1455/10465
medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283,1456/10465
current / past,C0521116;C0521116;C1705970;C1705970,1457/10465
rosuvastatin n = nmbr,C0965129,1458/10465
pulse rate ( bpm ),C0232117,1459/10465
anti - cholinergics ( long - acting ),C0242896,1460/10465
primary + gusto severe bleeding,C0205225;C0205225;C0205225;C0439612;C0439612;C0439612;C0439631;C0439631;C0439631,1461/10465
mean age  years ( nmbr % ci ),C0444504;C2347634;C2348143,1462/10465
vertebrobasilar infarct,C0545733,1463/10465
alathosterol ( % ),,1464/10465
blood oxygenation  mean ± sd,,1465/10465
rf positive  %,C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660;C0748398;C0748398;C0748398;C0748398;C0748398;C1547111;C1547111;C1547111;C1547111;C1547111,1466/10465
sf - nmbr ( health transition score ),C0037712;C0037712,1467/10465
time since diagnosis of osteoarthritis — yr,,1468/10465
no . of days to homa - ir testing — median ( iqr ),,1469/10465
certolizumab group ( n = nmbr ),C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,1470/10465
nmbr - nmbr / week,C0053917;C0053917;C1334884;C1334884,1471/10465
pnmbrynmbr inhibitor,C1999216,1472/10465
previous cardiovascular disease !,C0205156;C1552607,1473/10465
acute and delayed reaction,C0205178,1474/10465
atenolol strategy,C0004147,1475/10465
nationality,C0027473,1476/10465
bl updrs : high,C0005918;C0006413;C1552663;C2827109,1477/10465
history of paroxysmal atrial fibrillation  n ( % ),C0729790,1478/10465
biomarker status,C0449442,1479/10465
nicotine pack - years,C0028040,1480/10465
congestive heart failure — no . ( % ) | |,,1481/10465
fibrin - specific,C0015982;C0015982,1482/10465
≥ nmbr . nmbr to < nmbr . nmbr years,,1483/10465
duration of hypertension ( years ),C0449238;C0449238;C2926735;C2926735,1484/10465
therapy ( asa nmbr / placebo nmbr ),C0039798;C0087111;C1363945,1485/10465
nmbr prolonged antithrombotic pretreatment ( n = nmbr ),C0053917;C1334884,1486/10465
isolated igt,C0205409;C1548221,1487/10465
pasi < nmbr *,C4528685,1488/10465
nmbr locf ),C0053917;C1334884,1489/10465
uacr ( mgg - nmbr ),,1490/10465
vorapaxar placebo nmbr - yr . km % rate,C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,1491/10465
change from baseline  adjusted mean ( nmbr % ci )  %,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,1492/10465
paclitaxel - eluting,C0144576,1493/10465
distal anastomosis ( % ),C0448964,1494/10465
< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),,1495/10465
atrial fibrillation  n ( % ),C0004238;C0344434;C1963067,1496/10465
uacr  mg / mmol ( interquartile range ) b,,1497/10465
fasting glucose  mmol / l  mean ± sd,,1498/10465
coronary artery bypass surgery,C0010055,1499/10465
prior cardiovascular event — no . ( % ),,1500/10465
concomitant atorvastatin dose  mg,C0521115;C0521115;C0521115,1501/10465
n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),C0369718;C0441922,1502/10465
etanercept,C0717758,1503/10465
aortic stenosis  n ( % ),C0003507,1504/10465
pretreatment / concomitant treatment,C1550147;C1550147;C1550147;C1550147;C1550147;C1550147;C1550147;C2709094;C2709094;C2709094;C2709094;C2709094;C2709094;C2709094;C3539075;C3539075;C3539075;C3539075;C3539075;C3539075;C3539075;C3539076;C3539076;C3539076;C3539076;C3539076;C3539076;C3539076,1505/10465
circumflex,C1880089,1506/10465
diuretic drugs  n ( % ),C0012798;C0012798,1507/10465
baseline median ( iq range ),C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,1508/10465
serum sodium — meq / liter,,1509/10465
pacific islander,C0242191,1510/10465
hbalc > = nmbr % ( n - nmbr ),,1511/10465
hbanmbrc ( % ) all countries,,1512/10465
prior diabetes,C0332152;C0332152;C2826257;C2826257,1513/10465
number of events / patients,C4330837;C2360800;C2360800,1514/10465
coronary heart disease,C0010054;C0010068;C1956346,1515/10465
mean sgrq total score ( sd ),C3533236;C3533236;C0444504;C2347634;C2348143,1516/10465
managed medically — no . / total no . ( % ),,1517/10465
postoperative glucocorticoid use,C0032790;C0032790;C0032790,1518/10465
losartan + placebo,C0126174;C0126174;C0126174,1519/10465
geographical region ( % ),C0017446,1520/10465
serum haemoglobin anmbrc concentration ( % )  mean ( sd ),C0683149;C0229671;C0229671;C0229671;C1546774;C1546774;C1546774;C1550100;C1550100;C1550100,1521/10465
creatinine ≥ nmbr . nmbr mg / dl,,1522/10465
previous balloon angioplasty  n ( % ),C0205156;C0205156;C1552607;C1552607,1523/10465
thrombolytic treatment before randomization,C0016018;C0016018;C0016018;C0016018;C0016018;C0016018;C0016018;C0520997;C0520997;C0520997;C0520997;C0520997;C0520997;C0520997,1524/10465
apixaban,C1831808,1525/10465
urgent cor revasc,C0439609;C0439609;C3272275;C3272275,1526/10465
diabetic treatments !,C0241863,1527/10465
primary ep ( cvd / mi / ri ),C0205225;C0205225;C0439612;C0439612;C0439631;C0439631,1528/10465
cv death / mi / stroke,C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503,1529/10465
ticlopidine ( n = nmbr ),C0040207,1530/10465
alt  ast  or both > nmbrx uln,C1266129;C4553172,1531/10465
qualifying nstemi  n ( % ),C1514624;C1514624,1532/10465
baseline nihss score  median ( range ),C0168634;C1442488,1533/10465
scr  gmol / l,C1539487;C4050416,1534/10465
baseline cardiovascular medication  c n ( % ),C0168634;C1442488,1535/10465
thienopyridine drug at start of open - label period,C1120149;C1120149,1536/10465
egfr ( mumin / nmbr . nmbr mnmbr ),C1739039;C3811844;C3812682,1537/10465
median ( sd )  mg / mmol,C0549183;C0876920;C2347635;C2348144;C2939193,1538/10465
double - vessel disease  n ( % ),C0205173;C1705764;C1705765,1539/10465
lipid profile,C0023779;C0023779,1540/10465
chronic obstructive pulmonary disease,C0024117,1541/10465
treatment difference  ml,C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,1542/10465
homa - ir  median ( qnmbr  qnmbr ),C0022065;C0022071;C1448132,1543/10465
nmbr placebo n = nmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,1544/10465
concomitant mtx use  n ( % ),C0521115;C0521115;C0521115;C0521115;C0521115;C0521115,1545/10465
atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651,1546/10465
dmard | |,C0242708,1547/10465
calculated ldl cholesterol ( week nmbr ),C0444686;C0444686;C1441506;C1441506,1548/10465
median ( qnmbr : qnmbr ) total daily insulin dosenmbr,C0549183;C0876920;C2347635;C2348144;C2939193,1549/10465
hematologic,C0018943;C0205488,1550/10465
physician global assessment ( nmbr - nmbr mm vas ),C4050369,1551/10465
ipf - related,C0034069;C0034069;C1800706;C1800706,1552/10465
history of major bleeding,C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062,1553/10465
fpg  mean ( sd )  mmol / l,,1554/10465
ldl - c ( bq ) ( mg / dl ) - mean ± sd,,1555/10465
body - mass index  !  waist - to - hip ratio,C0005893;C0578022;C1305855,1556/10465
hba  % nmbrc,C0019016;C1825777;C3538758,1557/10465
current tobacco abuse  n ( % ),C0521116;C1705970,1558/10465
hormone therapy,C0279025,1559/10465
total group ( n = nmbr ),C0439175;C0439175;C0439175;C0439175;C0439175;C0439175;C0439810;C0439810;C0439810;C0439810;C0439810;C0439810,1560/10465
smoking pack year ( years ) fl,C0037369;C0453996;C1881674,1561/10465
( nmbr % ell ' ll  * non - hdl - c,C0053917;C0053917;C1334884;C1334884,1562/10465
terol  hdl - c  high - density lipoprotein cholesterol ,,1563/10465
age at first seizure  years  mean ( sd ),C0001779;C0001779;C0001779;C0001779;C0001779;C0001779,1564/10465
glomerular,C0022663;C0268731,1565/10465
median blood eosinophil count  cells per pla,C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193,1566/10465
cv death or first hhf,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,1567/10465
balloon angioplasty plus abciximab,C0002996;C0002997,1568/10465
lipoprotein ( a )  median ( ql  qnmbr )  nmol / l,C0065058;C0125953;C1096202;C1439335,1569/10465
osteoporosis,C0029456;C4554622,1570/10465
acute rheumatic disorders,C0001314,1571/10465
intensive control,C0162425;C0162425;C0162425;C0162425;C0162425;C0162425;C0522510;C0522510;C0522510;C0522510;C0522510;C0522510;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1550453;C1550453;C1550453;C1550453;C1550453;C1550453,1572/10465
treatment duration  days,C0444921;C3259042,1573/10465
warfarin ( n = nmbr ),C0043031,1574/10465
reported hypertension *,C0684224;C0684224;C0700287;C0700287;C4319718;C4319718,1575/10465
before bronchodilation,C1371299;C3537072,1576/10465
ccv history / condition at baseline,C0683519;C0683519,1577/10465
ivabradine ( n = nmbr ),C0257190,1578/10465
bmi ( nmbr . nmbr  nmbr . nmbr ),C0578022,1579/10465
physical function ( nmbr - nmbr  short form - nmbr subscale ),C0516981;C4049916,1580/10465
prior cerebrovascular disease,C0332152;C2826257,1581/10465
reason for enrollment in active a — no . ( % ),,1582/10465
medical characteristics,C0199168;C0205476,1583/10465
medication use at baseline — no . ( % ),,1584/10465
age < nmbr years — no . ( % ),,1585/10465
planned valve surgery  n ( % ),C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732,1586/10465
time from randomization to pci ( st - elevation mi )  min,C0040223;C3541383,1587/10465
haq - di score ( nmbr - nmbr ),C3826998;C3826998;C4321476;C4321476,1588/10465
mean ( sd ) dasnmbr - nmbr ( esr ) *,C0444504;C2347634;C2348143,1589/10465
randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,1590/10465
v alsartan / hctz  n ( % ),C0020261,1591/10465
nmbr year or more,C0053917;C0053917;C1334884;C1334884,1592/10465
crcb - ( ml / min )  mean ( s . e . ),,1593/10465
three - vessel disease,C3272265,1594/10465
st - segment depression > nmbr . nmbr mv on admission  %,C0520887,1595/10465
planned treatment duration  n ( % ),C4528394,1596/10465
z\tonastaiin,,1597/10465
inadequate response / intolerance to prior therapy  %,C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856,1598/10465
change from baseline in dasnmbr - esr  meannmbr sd,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,1599/10465
cause of heart failure — no . ( % ),,1600/10465
predominant type of heparin,C1542147;C1542147;C1542147;C1542147,1601/10465
western europe / australia / israel,C0043128;C0043129,1602/10465
preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0445204;C0445204;C0445204,1603/10465
glucose  mmol / l,C0017725,1604/10465
aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,C0004057,1605/10465
retinopathy — %,,1606/10465
pulmonary embolism,C0034065,1607/10465
mild or moderate copd,C2945599,1608/10465
prior ml ( before index acs ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,1609/10465
diabetes duration ( known )  % of patients,C0011847;C0011847;C0011849;C0011849,1610/10465
creatinine clearance ， : : nmbr ml / min  %,,1611/10465
baseline hb < nmbr g nmbr nmbr n = nmbr,C0168634;C0168634;C1442488;C1442488,1612/10465
joint swelling,C0152031,1613/10465
nmbrmwd decrease > nmbr m,C0392756;C0547047,1614/10465
profound thrombocytopenia ( < nmbrxnmbr / l ),C0439808;C0439808,1615/10465
body mass index  median  ( nmbrth — nmbrth percentiles )  kg / mnmbr,,1616/10465
associated with connective tissue disease,C0332281,1617/10465
postbronchodilator lung function at screening,C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594,1618/10465
non – small - cell lung cancer,,1619/10465
prior anti - tnf therapy — no . ( % ),,1620/10465
all rosuva,,1621/10465
peripheral edema,C0085649,1622/10465
insulin - na ' ive,C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501,1623/10465
gender  women n  % ),C0079399;C1522384,1624/10465
mean ( sd ) swollen joint count *,C0444504;C2347634;C2348143,1625/10465
diuretic drugs ( excluding antialdosterone ),C0012798;C0012798,1626/10465
hfpef ( ef n nmbr )  ( % ),,1627/10465
extent of disease  n ( % ),C0449279;C4553144,1628/10465
tendonitis,C0039503,1629/10465
previous hypertension,C0205156;C0205156;C1552607;C1552607,1630/10465
oral contraceptives,C0009905,1631/10465
syncope — no . ( % ),,1632/10465
anatomic complexity characteristics,C0502371;C0502371,1633/10465
conventional treatment,C2945704,1634/10465
left circumflex,C0205091;C0443246;C1552822,1635/10465
amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0002598,1636/10465
number of pack - years,C0237753;C0449788,1637/10465
baseline cardiac biomarkers,C0168634;C0168634;C1442488;C1442488,1638/10465
type nmbr diabetes duration  mean ( sd )  years,C1320657;C1320657;C1320657;C1320657,1639/10465
oral study drug administered — no . / total no . ( % ),,1640/10465
diltiazem or verapamil,C0012373,1641/10465
major bleeding ( statin use vs non - use ),C0205082;C0205164;C4318856;C4521762,1642/10465
placebo secukinumab pooled,C0032042;C1696465;C1706408,1643/10465
bilateral disease ( % ) ' j ' ' j ',C1511113,1644/10465
pathological q waves,C0429090,1645/10465
leukocytes  nmbr / nl,C0023516,1646/10465
lipid - lowering agents ( % ),C0086440,1647/10465
history of second prior mi,C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,1648/10465
study medication — no . ( % ),,1649/10465
laboratory data  mean ( sd ),C0022877;C0022877;C0022877;C3244292;C3244292;C3244292;C4283904;C4283904;C4283904,1650/10465
p value ( men versus women ),C1709380,1651/10465
former n z nmbr,C0205156;C0205156;C0750523;C0750523,1652/10465
insulin : glucose ratio,C0021641;C1533581;C1579433;C3714501,1653/10465
tnmbrdm duration ( years ),C0449238;C2926735,1654/10465
serum creatinine > nmbr pmol / l . n ( % ) |,C0201976;C0600061,1655/10465
kellgren and lawrence radiographic reading grade nmbr — no . ( % ),,1656/10465
data missing or no drug given,C1511726;C1511726;C1511726;C3245479;C3245479;C3245479;C3714741;C3714741;C3714741,1657/10465
gpiib / iiia receptor inhibitor,C0016011,1658/10465
ethnic origin,C0015031,1659/10465
supine after nmbr minutes change from baseline,C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846,1660/10465
omega - nmbr fatty acid ( n = nmbr ),C1719844;C1719844,1661/10465
pulmonary rales  n ( % ),C0034642,1662/10465
< nmbr months  n ( % ),C0053917;C1334884,1663/10465
fibrinogen  g / l,C0016006;C1167394;C2587184;C3540039,1664/10465
right ventriculardysfunction atinclusion,C0205090;C0444532,1665/10465
nace ( primary endpoint ),,1666/10465
micro - / macro - albuminuria  ckd and / or retinopathy,C0085672;C1553035;C3811161;C4049106,1667/10465
interaction : treatment by psoriasis p valuenmbr,C1704675,1668/10465
score > nmbr %  % of patients,C0449820;C4050231,1669/10465
any aes  n ( % ),C1412268;C2699274,1670/10465
ace inhibitors or angiotensin ii,C0003015,1671/10465
des ( % previous stenting ),C0011702;C0011702;C0011702;C0011702;C4551552;C4551552;C4551552;C4551552,1672/10465
comparison with placebo ( mean,C1707455;C1707455;C1707455,1673/10465
mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143,1674/10465
exercise,C0015259;C1522704,1675/10465
vascular territory # nmbr,C0005847;C0005847;C0005847;C0005847;C1558950;C1558950;C1558950;C1558950;C1801960;C1801960;C1801960;C1801960,1676/10465
native hawaiian or other pacific islander,C0337920,1677/10465
control baseline ( n - nmbr ),C0243148;C0243148;C1550141;C1550141;C1882979;C1882979;C2587213;C2587213;C3274648;C3274648;C4553389;C4553389,1678/10465
rando . in na * *,,1679/10465
estimated glomerular filtration rate - ml / min  median ( iqr ) ',C3811844,1680/10465
nyha class within past month — no . / total no . ( % ),,1681/10465
aspirin group,C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,1682/10465
non - hdl - c ( mg / dl ) - mean ± sd,,1683/10465
fibrinolytic for qualifying event,C0040044;C0040044,1684/10465
nmbr degree of ica stenosis 丰,,1685/10465
calcium - channel blockers ( % ),C0006684;C2757014,1686/10465
duration of ra ( years ),C0449238;C0449238;C2926735;C2926735,1687/10465
min  max,C0702093;C1524029;C3813700,1688/10465
estimated gfr  < nmbr ml min - nmbr nmbr . nmbr m - nmbr  n ( % ) a,C0750572;C0750572,1689/10465
ctn - l  ng / ml,C0917591,1690/10465
chd + cerebral infarction,C0280604;C3542407,1691/10465
fenofibric acid + moderate - dose statin,C0060179,1692/10465
highest tg tertile,C1522410,1693/10465
days of study - drug administration ( % ) * * nmbr day,C2826182;C2826182,1694/10465
emotional role,C0013987;C0013987;C0013987;C0849912;C0849912;C0849912,1695/10465
antithrombotic therapy,C0039798;C0087111;C1363945,1696/10465
periprocedural medications — no . / total no .,,1697/10465
kim nmbr ( pg / ml ),C0053917;C1334884,1698/10465
mi or cad,C3810814,1699/10465
d - dimer levelsatinclusion,C0060323,1700/10465
any immunosuppressive agent,C0021081,1701/10465
tender joint count  of nmbr,C0451530,1702/10465
increased waist circumference,C0205217;C0442805,1703/10465
cross - damp time : < l : llhrs : min ( n = nmbr ),C2828360;C2828360;C2828360;C2828360,1704/10465
aspirin only ( n = nmbr  nmbr ),C0004057;C0004057,1705/10465
high risk with atherosclerotic vascular disease *,C0332167;C3272283;C4050568;C4319571,1706/10465
metrex overall modified intention - to - treat population ? :,C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607,1707/10465
basmi ( linear )  mean ( sd ),,1708/10465
cor revasc,C0018787;C0056331,1709/10465
high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,1710/10465
adl subscale ( range  nmbr - nmbr ) *,C0001288;C1420005,1711/10465
baseline statin usec,C0168634;C1442488,1712/10465
unbound pcsknmbr ( nmol / l ),,1713/10465
months from mi — median ( iqr ),,1714/10465
enthesitis count,C1282952;C1282952,1715/10465
enalapril,C0014025,1716/10465
history of alcohol use,C0551571;C0552479,1717/10465
initiation of dialysis  renal transplantation  or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l ),C0589507;C0589507;C0589507;C0589507;C1158830;C1158830;C1158830;C1158830;C1704686;C1704686;C1704686;C1704686,1718/10465
female race / ethnicity,C0043210;C0043210;C0043210;C0043210;C0043210;C0043210;C0086287;C0086287;C0086287;C0086287;C0086287;C0086287;C1705497;C1705497;C1705497;C1705497;C1705497;C1705497;C1705498;C1705498;C1705498;C1705498;C1705498;C1705498,1719/10465
bsa affected  mean ± sd  %,,1720/10465
timing of clopidogrel loading dose,C0449243;C1704250,1721/10465
week nmbr fpg  mean ( s . e . ),C0332174;C0332174;C0439230;C0439230,1722/10465
crohn ' s disease - related medication at baseline  n ( % ),C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346,1723/10465
post - menopausal ( a ),C0232970,1724/10465
saxagliptin nmbrmg ( n z nmbr ),C1611934,1725/10465
weight ( range ) ( kg ),C0005910;C0043100;C1305866;C1705104,1726/10465
monotherapy,,1727/10465
small vessel,C0225988,1728/10465
history of microvascular disease — no . ( % ),,1729/10465
baseline sitosterol,C0168634;C0168634;C1442488;C1442488,1730/10465
hypertension and left ventricular hypertrophy,C0020538;C1963138,1731/10465
ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,C0023668;C0023668;C0023668,1732/10465
severe n z nmbr,C0205082;C0205082;C4050465;C4050465;C4050466;C4050466,1733/10465
arthritis,C0003864;C4552845,1734/10465
concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,,1735/10465
extensive,C0205231,1736/10465
baseline corticosteroids *,C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,1737/10465
lv hypertrophy  n ( % ),C0149721,1738/10465
sex ( interaction : p = nmbr . nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,1739/10465
native hawaiian / other,C0337920,1740/10465
pain ( nmbr - nmbr mm vas ),C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132,1741/10465
randomized,C0034656;C3815594,1742/10465
nmbrbaseline mean,C0444504;C2347634;C2348143,1743/10465
fc - ldl - c  mg / dl,C2983605,1744/10465
patients with previous loss of response to and intolerance of infliximab *,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,1745/10465
other glp - nmbr receptor agonist,C0018301;C0018301;C1422069;C1422069;C1425391;C1425391;C1539338;C1539338;C2350813;C2350813,1746/10465
baseline hematocrit  median ( iqr ),C0168634;C0168634;C1442488;C1442488,1747/10465
placebo event rate ( n = nmbr )  %,C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408,1748/10465
history of amputation,C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,1749/10465
low - dose rivaroxaban + aspirin group,C2608320;C2608320;C2608320;C2608320;C2608320;C2608320,1750/10465
documented asymptomatic cardiac ischemiac,C1301725;C1301725;C1609436;C1609436,1751/10465
seropositive ( rf + ve and / or acpa + ve ) subgroup,C0521143,1752/10465
| ? ) - blocker  %,,1753/10465
metabolizer phenotype ( % ) §,,1754/10465
disease location / type : terminal ileum,C0457464;C0457464;C0457464;C0457464,1755/10465
selexipag ( n = nmbr ),C2000145,1756/10465
clinical presentation,C2708283,1757/10465
patients not receiving corticosteroids at baseline,C0030705,1758/10465
alteplase group ( n = nmbr ),C0032143;C0032143;C0032143;C0032143;C0032143;C0032143,1759/10465
obesity  % *,C0028754;C1963185,1760/10465
cardiovascular history — no . / total no . ( % ),,1761/10465
cardiac therapy  n ( % ) d,C3654025,1762/10465
femoral access — no . / total no . ( % ),,1763/10465
laboratory data,C0022877;C0022877;C0022877;C3244292;C3244292;C3244292;C4283904;C4283904;C4283904,1764/10465
other drugs,C0013227;C3687832,1765/10465
apob : apoa - nmbr ratio,C0003593;C3252643,1766/10465
length of stay ( randomization to discharge  h ),C0023303,1767/10465
nmbr - aminosalicylates | | | |,C0053917;C1334884,1768/10465
peripheral - artery disease ( % ),C1704436;C4025272,1769/10465
severity of the disease ( gold nmbr )  n ( % ),C0521117,1770/10465
apixaban  nmbr . nmbr mg,C1831808,1771/10465
coronary bypass graft,C1260596,1772/10465
vascular disease indicator no ( n = nmbr ),C0042373;C0042373;C0042373,1773/10465
laboratory values at randomization ( median and iqr ),C0022877;C3244292;C4283904,1774/10465
acr  mg / mmol,C1412134;C1515941,1775/10465
tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,1776/10465
hbanmbrc at baseline  %,C0168634;C1442488,1777/10465
indication for stent,C0392360;C3146298,1778/10465
history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,C2315493,1779/10465
months since ra was first diagnosed  mean ( sd ),C0439231,1780/10465
hemorrhagic stroke ( n = nmbr ),C0553692,1781/10465
mini - mental state examination,C0451306,1782/10465
number of stents implanted,C0237753;C0449788,1783/10465
risk score category ( points ),C0035647;C0035647;C0035647;C0035647;C4552904;C4552904;C4552904;C4552904,1784/10465
microvascular complications  n ( % ) ’,,1785/10465
erosion score  median ( min  max ),C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,1786/10465
fevnmbr / fvc ( post salbutamol ),C3714541,1787/10465
type nmbr diabetes,C1320657;C1320657,1788/10465
% predicted pre - bronchodilator fevnmbr  % *,C0681842;C1882327,1789/10465
patients receiving corticosteroids at baseline,C0030705,1790/10465
odds ratio adj ( nmbr % cl ),C0028873;C0028873;C0028873;C0028873,1791/10465
no statin vs statin alone vs any statin plus other llt,C0360714,1792/10465
general and lumbar epidural,C0205246;C3812897;C3891294;C4521767,1793/10465
rf and acpa negativenmbr,C0035448;C0201660;C0748398;C1547111,1794/10465
hispanic,C0086409,1795/10465
onsetofaf  no . ( % ),,1796/10465
percentage with disease duration < nmbr years,C0439165;C1549488;C1561533,1797/10465
doubling of creatinine †,,1798/10465
diameter stenosis  mean ( sd )  %,C1301886;C1301886;C1301886,1799/10465
biologic naive,C0005515;C0205460,1800/10465
systemic corticosteroids  n ( % ) a,C4053960,1801/10465
europe ( non - eu ),C0015176,1802/10465
fasting blood glucose ( mg / dl ),C0428568;C1261430,1803/10465
fevnmbr reversibilityz ( pre / post ipratropium )  %,,1804/10465
mean eosinophil count  per ml,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,1805/10465
men  total ( n 二 nmbr ),,1806/10465
rhabdomyolysis  myopathy  or myalgia with ck elevation > nmbrx uln,C0035410;C4552660,1807/10465
rf positive  n ( % ),C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660;C0748398;C0748398;C0748398;C0748398;C0748398;C1547111;C1547111;C1547111;C1547111;C1547111,1808/10465
without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501,1809/10465
hospitalized for heart failure during that time period,C0701159;C0701159;C0701159,1810/10465
phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),C0031676;C0031676;C0202177;C0202177,1811/10465
clinical and laboratory measurements,C0205210,1812/10465
current medication — no . ( % ),,1813/10465
infliximab nmbr mg / kg,C0666743;C0666743,1814/10465
randomization - to -,C0034656,1815/10465
low hdl cholesterol,C0151691,1816/10465
history of chronic hf,C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062,1817/10465
race - non - white ( n = nmbr  nmbr ),C0034510;C0034510;C0034510;C1706779;C1706779;C1706779;C3853635;C3853635;C3853635,1818/10465
moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,1819/10465
sfc nmbr / nmbr mg twice daily ( n = nmbr ),C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536,1820/10465
time since diagnosis of type nmbr diabetes,C0040223;C3541383,1821/10465
riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),C0683610;C4553947,1822/10465
disease and quality - of - life scores,C0012634,1823/10465
laba / ics use at screening  n ( % ),C0815320;C4551720,1824/10465
mean change in radiographic end points,C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,1825/10465
screening % predicted fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,1826/10465
lntensityd,,1827/10465
steroid use at baseline,C0281991;C0281991,1828/10465
angina class at baseline,C0002962;C0002962;C0002962;C0002962;C0002962;C0002962,1829/10465
emotional status,C0013987;C0849912,1830/10465
albuminuria ( g / g ),C0001925,1831/10465
concomitant therapy,C1707479,1832/10465
thrombophilia,C0398623,1833/10465
mean — mg / dl level — no . ( % ),,1834/10465
urine albumin - to - creatinine ratio - no . ( % ) § §,,1835/10465
mean a ± sd ( mmhg ),,1836/10465
hdl cholesterol ( week nmbr ) a,C0023822;C0392885,1837/10465
low - dose rivaroxaban plus aspirin ( n = nmbr ),C2608320,1838/10465
clinical criterianmbr,C0205210,1839/10465
abatacept ( n = nmbr * ),C1619966,1840/10465
ind nmbr gg q . d . n / n ( % ),C4049864;C4049864;C4049864;C4049864,1841/10465
lvef ( % )  mean ± sd,,1842/10465
menopausal status and use of hrt ( % ) y,C1513126,1843/10465
renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920,1844/10465
urine albumin - to - creatinine ratio,C0455271;C1318330,1845/10465
total n = nmbr n ( % ),C0439175;C0439810,1846/10465
chronic heart failure,C0018802;C0264716,1847/10465
type nmbr diabetes mellitus ’,,1848/10465
mean score on dasnmbr - nmbr ( crp ) ^,C3533236;C3533236,1849/10465
orthostatic hypotension,C0020651,1850/10465
previous oral glucose - lowering agents  % of patients,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,1851/10465
aortic stenosis,C0003507,1852/10465
no . of patients / total no . ( % ),,1853/10465
any dose reduction,C0178602;C0178602;C0178602;C0178602;C0869039;C0869039;C0869039;C0869039;C1114758;C1114758;C1114758;C1114758,1854/10465
hazard ratio for event ( nmbr % ci ),C2985465;C2985465,1855/10465
prior implantable cardiodefibrillator  n ( % ),C0332152;C2826257,1856/10465
crp ( mg / l )  median ( min  max ),C3890735;C4048285,1857/10465
gold nmbr groups  n ( % ),C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897,1858/10465
enalapril + aliskiren dm = nmbr non - dm = nmbr,C0014025;C0014025,1859/10465
ics  mg / day,C0815320;C4551720,1860/10465
psoriasis covering > nmbr % bsa  n ( % ) §,,1861/10465
antihypertensive drug  %,C0003364,1862/10465
mean ( sd ) post - bronchodilator fevnmbr reversibility  %,C0444504;C2347634;C2348143,1863/10465
nmbr - nmbr ( severe ),C0053917;C1334884,1864/10465
stroke or pvd  ( % ),C0038454;C4554100,1865/10465
cabg > nmbr month ago,C0010055,1866/10465
history of percutaneous coronary intervention,C1320647;C4554713,1867/10465
current or previous atrial fibrillation,C0521116;C1705970,1868/10465
ace - inhibitor use,C0003015;C0003015;C0003015;C4541021;C4541021;C4541021,1869/10465
anemia — no . ( % ) | |,,1870/10465
low - dose corticosteroid user,C0445550;C0445550;C0445550;C0445550;C1708745;C1708745;C1708745;C1708745,1871/10465
upper gastrointestinal,C3203348,1872/10465
cad history and risk factors  n ( % ),C1504769;C1504769;C1504769;C1504769;C1504769;C1504769;C2239547;C2239547;C2239547;C2239547;C2239547;C2239547;C3813548;C3813548;C3813548;C3813548;C3813548;C3813548;C4284121;C4284121;C4284121;C4284121;C4284121;C4284121,1873/10465
das - nmbr ( crp ) < nmbr . nmbr  n ( % ),C0051767;C0051767;C0057671;C0057671,1874/10465
repaired chd,C0205340;C0205340,1875/10465
gusto - defined bleeding,C1704788;C3539106,1876/10465
peripheral vasodilators,C0724804,1877/10465
mean ( sd ) number of albuterol per day  puff,C0444504;C2347634;C2348143,1878/10465
liraglutide ( n = nmbr  nmbr ),C1456408,1879/10465
angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534,1880/10465
perianal or anus,C0442158,1881/10465
framingham nmbr - year cv risk score,C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866,1882/10465
native coronary - artery lesions,C0302891,1883/10465
current drinker,C0556297,1884/10465
placebo ls means ( n ),C0032042;C1696465;C1706408,1885/10465
( %  nmbr % cl ),,1886/10465
duration of disease  years,C0872146,1887/10465
musculoskeletal,C0497254;C2707260,1888/10465
severe ( gold nmbr ),C0205082;C4050465;C4050466,1889/10465
moderate thrombocytopenia ( < nmbrxnmbr / l ),C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,1890/10465
st change > nmbr mm,C0036056;C0036056;C0036056;C0036056;C3272372;C3272372;C3272372;C3272372,1891/10465
received an oral aha within nmbr weeks prior to screening,C1514756,1892/10465
stiffness subscale,C0427008,1893/10465
egfr < nmbr  n ( % ),C1739039;C3811844;C3812682,1894/10465
rec . ischemia requiring revasc,C1424025;C1424025;C2606415;C2606415,1895/10465
type of concomitant statin,C0332307;C1547052,1896/10465
bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0578022,1897/10465
moderate ( nmbr risk factor ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,1898/10465
timi risk score nmbr - nmbr,C0035647;C0035647;C0035647;C0035647;C4552904;C4552904;C4552904;C4552904,1899/10465
chronic obstructive pulmonary disease  n ( % ),C0024117,1900/10465
glycopyrronium nmbr mg ( n = nmbr ),C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772,1901/10465
history of microvascular eye disease 本  n ( % ),,1902/10465
oral aminosalicylates,C0442027;C4521986,1903/10465
bmi kg - m - nmbr,C0578022;C0578022,1904/10465
mean ± sd triglycerides  mg / dl,,1905/10465
type of des,C0332307;C0332307;C1547052;C1547052,1906/10465
white  n ( % ),C0007457;C0043157;C0220938,1907/10465
aspirin / antiplatelet,C0004057,1908/10465
any peripheral arterial disease,C0085096;C1704436,1909/10465
ldl cholesterol mean ( mg / dl ± sd ),,1910/10465
index event — no . ( % ),,1911/10465
hospital factor # nmbr,C0019994;C0019994;C0019994;C0019994;C1510665;C1510665;C1510665;C1510665,1912/10465
baseline tobacco use,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,1913/10465
persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,C0741008;C0741008;C0741008;C0741008,1914/10465
previously taken tnfi  %,,1915/10465
troponin t,C0077404;C1420827,1916/10465
exacerbations in the previous year,C4086268;C4086268;C4086268;C4086268,1917/10465
omega - nmbr fatty acid,C1719844;C1719844,1918/10465
stroke risk score,C1277291;C1277291,1919/10465
daily insulin dose  mean ( sd )  iu,C2348070;C2348070;C2348070;C2348070;C0332173,1920/10465
former or never,C0205156;C0750523,1921/10465
type nmbr diabetes duration  years,C1320657;C1320657;C1320657;C1320657,1922/10465
ccv history / condition,C0683519,1923/10465
microalbuminuria or proteinuria,C0730345,1924/10465
absolute risk difference ( ci )  % *,C1549031;C1549031;C1519101;C1519101,1925/10465
elevated at wk nmbr — no . ( % ) nmbr,,1926/10465
proctosigmoiditis,C0033252,1927/10465
mean age ( years ) race,C0444504;C2347634;C2348143,1928/10465
cat total score,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282,1929/10465
nmbr no . of events,C0053917;C1334884,1930/10465
intervention group ( n = nmbr ),C2986530,1931/10465
( nmbr % cl ) interaction,C0053917;C1334884,1932/10465
apoa - nmbr  g / l,C0003592;C0003592;C0523508;C0523508;C4553344;C4553344;C4553379;C4553379,1933/10465
yes  insulin - treated,C1549445;C1705108;C1710701,1934/10465
epa treatment ( n = nmbr ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,1935/10465
responders of three - item end point at nmbr weeks *,C0205449;C0205449;C0205449;C0205449,1936/10465
systemic glucocorticoid use at randomisation,C0205373;C0205373;C0205373,1937/10465
duration of tnmbrdm  y,C0449238;C2926735,1938/10465
ace inhibitors or angiotensin ii blockers,C0003015,1939/10465
physician ' s global assessment of dis -,C4050369;C4050369;C4050369,1940/10465
clopidogrel no . of patients % ),C0070166,1941/10465
duration of crohn ' s disease ( yrs ),C0449238;C2926735;C0010346,1942/10465
multivessel intervention  n ( % ),C0184661;C0886296;C1273869,1943/10465
tertile nmbr,C0053917;C1334884,1944/10465
cabg surgery,C0010055;C0010055;C0010055;C0010055,1945/10465
crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l )  n ( % ),C3890735;C3890735;C3890735;C4048285;C4048285;C4048285,1946/10465
fatal and nonfatal stroke,C1302234;C1705232,1947/10465
angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,,1948/10465
ace - i / arb  ( % ),C1452534;C1452534;C4284014;C4284014,1949/10465
gliclazide ( modified release ) 一 no . ( % ) ^,,1950/10465
conventional treatment ( n = nmbr ),C2945704,1951/10465
currentother ( notpredefined ) medical conditions,,1952/10465
history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,1953/10465
concomitant conventional dmard use,C0521115;C0521115;C0521115,1954/10465
dual antiplatelet,C0205173;C1554184,1955/10465
digitalis,C0012252;C0304520,1956/10465
active or previous cancer,C0205177;C3853793;C3888249,1957/10465
therapy at discharge,C0039798;C0039798;C0039798;C0087111;C0087111;C0087111;C1363945;C1363945;C1363945,1958/10465
north america hr ( nmbr % cl ),C0028405,1959/10465
intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205103;C1550465;C2827755;C3889971,1960/10465
male sex — no . ( % ) race — no . ( % ) ) :,,1961/10465
primary end point kaplan - meier rate  %,C2986535;C2986535,1962/10465
all ~ cause mort / hf hosp .,C0015127;C0015127;C0015127;C0015127;C1524003;C1524003;C1524003;C1524003,1963/10465
haemodynamics and lv function,C0019010;C4281788,1964/10465
duration of study - drug infusion,C0449238;C0449238;C2926735;C2926735,1965/10465
salmeterol nmbr gg bid,C0073992;C0073992;C0073992;C0073992,1966/10465
p value for adjusted hr,C1709380,1967/10465
vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235,1968/10465
a / v ( n = nmbr ),,1969/10465
unknown,C0439673;C3541433;C4050014,1970/10465
ff / vi nmbr / nmbr pg od,C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348,1971/10465
ivabradine group,C0257190;C0257190;C0257190;C0257190;C0257190;C0257190,1972/10465
comparison with baseline ( mean,C1707455;C1707455,1973/10465
irofiban,,1974/10465
laba / lama,C0999593;C1416775,1975/10465
< nmbr years eze / simva,C0053917;C1334884,1976/10465
placebo ( dm - vs . dm + ),C0032042;C1696465;C1706408,1977/10465
o total randomized,C0483204;C0483204,1978/10465
cabgorptca,,1979/10465
total patients n = nmbr,C0439175;C0439810,1980/10465
left circumflex artery,C0226037,1981/10465
lebrikizumab ( n = nmbr ),C2981360,1982/10465
disease duration  median ( range ) years,C0872146,1983/10465
bl updrs : low,C0005918;C0006413;C1552663;C2827109,1984/10465
fevnmbr % reversibility,C0449261,1985/10465
lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0065058;C0065058;C0125953;C0125953;C1096202;C1096202;C1439335;C1439335,1986/10465
( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),C0053917;C1334884,1987/10465
very high risk,C0442804;C0442804;C4321397;C4321397;C0442824;C0442824;C0442824;C0442824;C2984081;C2984081;C2984081;C2984081,1988/10465
location of crohn ' s disease  %,C0450429;C1515974;C4284930;C4284931,1989/10465
baseline diabetes,C0168634;C0168634;C1442488;C1442488,1990/10465
number of vessels disease,C0237753;C0449788,1991/10465
patient history of disease n ( % ),C0030705;C0030705;C0030705;C0030705,1992/10465
tocilizumab ( n = nmbr ),C1609165,1993/10465
mean ( sd ) duration of smoking  pack years,C0444504;C2347634;C2348143,1994/10465
difference ( a ) vs placebo ( nmbr % cl ),C1705241;C1705242,1995/10465
nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,1996/10465
demographic characteristics,C0683970,1997/10465
ezetimibe use,C1142985;C1142985;C1142985,1998/10465
subset of patients on metformin,C1515021,1999/10465
nmbr vessels or left main,C0053917;C1334884,2000/10465
congenital shunts,C0009678;C0009678;C0009678;C1744681;C1744681;C1744681,2001/10465
eze / simva gender,C0079399;C1522384,2002/10465
methotrexate dose at baseline,C0025677;C0025677;C0025677;C0025677;C0025677;C0025677,2003/10465
neoplasia  n ( % ),C0027651;C1882062,2004/10465
mesothelin ( ng / ml ),C0380162;C1334533,2005/10465
non - smoker ( n = nmbr  nmbr ),C0337672;C0425293;C4554605,2006/10465
amlodipine / valsartan nmbr / nmbr mg / v = nmbr,C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523,2007/10465
> nmbr . nmbr hdl cholesterol level,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2008/10465
past or current angina pectoris,C1444637;C4284302,2009/10465
history of peripheral vascular disease,C1881056,2010/10465
group — no . ( % ),,2011/10465
number of treated vessels ( per patient ),C0237753;C0449788,2012/10465
ranolazine  n = inmbrinmbr,C0073633,2013/10465
prior failure of anti - tnf therapy — no . ( % ),,2014/10465
concomitant medications for ulcerative colitis — no . ( % ),,2015/10465
lipid - lowering therapy,C0585943,2016/10465
dlqi  nmbr - nmbr *,C3899393,2017/10465
patients treated for > nmbr weeks ( % ),C0030705,2018/10465
immunomodulatory agents,C0005525,2019/10465
endothelin - receptor antagonists,C1134681;C2266875,2020/10465
nt - probnp  median ( iqr )  pg / ml,C0669479;C0754710,2021/10465
hosp . for hf,,2022/10465
alcohol use ( > nmbr drink / wk ),C0001948,2023/10465
st - segment elevation mi,C0520886,2024/10465
history of dyspepsia,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,2025/10465
ncep risk category at study entry  n ( % ),C0035647;C0035647;C4552904;C4552904,2026/10465
treated hypertension :,C1522326;C1522326,2027/10465
presence of dactylitis  n ( % ),C0150312;C0392148;C3854307,2028/10465
placebo every nmbr weeks ( n = nmbr ),C0032042;C1696465;C1706408,2029/10465
heart rate  mean ± sd ( b . p . m . ),,2030/10465
post - bronchodilator fevnmbr  reversibility percentage of baseline value,C2599594,2031/10465
intense physical activity,C0522510;C0522510,2032/10465
concomitant drugs,C0521115;C0521115,2033/10465
cholesterol absorption inhibitor ( ezetimibe ),C0003277;C0003277;C0003277;C0003277;C0003277;C2945742,2034/10465
chanmbrdsnmbr - vasc score ( median  iqr ),C0449820;C4050231,2035/10465
serum potassium — mmol / liter,,2036/10465
nadroparin vs control,C0206232,2037/10465
type of event — no . ( % ),,2038/10465
stroke or tia — no . ( % ),,2039/10465
previous major bleeding,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,2040/10465
coexisting conditions,C0679225,2041/10465
characteristics of pulmonary embolism at inclusion,C1521970,2042/10465
time of symptom onset to randomization ( hrs ),C1320528,2043/10465
recurrent heart failure,C1455761;C1455761;C1455761;C2945760;C2945760;C2945760,2044/10465
all completers ( n nmbr nmbr ),,2045/10465
qualifying hbanmbrc ( % ),C1514624,2046/10465
medically important infectionsa,C3898777;C4084912,2047/10465
three arm,C0205449;C0205449;C0205449,2048/10465
after nmbr h,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,2049/10465
fevnmbr % pred,C0032952;C0044955,2050/10465
copd assessment test ( cat ) score,C4284282;C4284282,2051/10465
aspirin use ( > nmbr mg ),C0004057;C0004057;C0004057,2052/10465
moderate ( gold nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,2053/10465
no ascvd + additional cv risk factors  n ( % ),C3665365;C3665365;C3665365;C3665365;C3665365;C3665365,2054/10465
arb / ace,C3888198;C3888198,2055/10465
hypertension serum lipid values,C0020538;C1963138,2056/10465
measured at clinic visit with usual device,C0444706;C3541902,2057/10465
average maximum cimt ( mm ),C1510992;C1510992;C1510992;C2825518;C2825518;C2825518,2058/10465
thrombophilia  no . ( % ) e,C0398623,2059/10465
health assessment questionnaire - disability index,C4321476,2060/10465
median ( qnmbr : qnmbr ) lp ( a )  mg / dl,C0549183;C0876920;C2347635;C2348144;C2939193,2061/10465
any clinical ae,C0205210,2062/10465
mean ( sd ) feno  ppb,C0444504;C2347634;C2348143,2063/10465
cdai score §,,2064/10465
unfractionated,,2065/10465
physical and cognitive examination : ! :,C0031809;C0205485;C1509143,2066/10465
syst . bp ( mmhg ),C0037623;C1415692;C1708288;C4318478,2067/10465
medications at discharge or day nmbr  if earlier ( % ),C0806915,2068/10465
drug discontinuation not due to death,C0013227;C0013227;C0013227;C1254351;C1254351;C1254351,2069/10465
congestive heart failure ( < nmbr wk ),C0018802,2070/10465
aliskiren,C1120110,2071/10465
physician global assessment of disease activity ( vas nmbr - nmbr mm ),C4050369,2072/10465
baseline dlco . mmol kpa - ’ -,,2073/10465
role emotional,C0035820;C0035820;C1705810;C1705810;C3871154;C3871154,2074/10465
baseline ( geometric mean  cv ),C0168634;C1442488,2075/10465
pah classification,C0030123;C0030123;C0030123;C3203102;C3203102;C3203102;C4284467;C4284467;C4284467,2076/10465
days without albuterol use  * %,C0439228;C0439228;C0439228,2077/10465
simva ( % ),,2078/10465
treatment with open - label perindopril,C3640652,2079/10465
new diabetes — no . ( % ),,2080/10465
adjusted change from baseline mean ( s . e . ),C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081,2081/10465
$ nmbrand  nmbr years,,2082/10465
fpg ( range ) ( mmol / l ),,2083/10465
arterial graft,C0450140,2084/10465
any established coronary artery disease,C0443211;C0443211;C0443211;C1272684;C1272684;C1272684,2085/10465
time to treatment ( min ) t,C3494202,2086/10465
serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),C0302353;C0543465,2087/10465
hemoglobin concentration — g / liter,,2088/10465
clopidogrel + aspirin ( n = nmbr ),C0070166,2089/10465
previous metformin use  %,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,2090/10465
current ( % ),C0521116;C1705970,2091/10465
ecg findings at baseline — no . ( % ),,2092/10465
concomitant therapies n ( % ),C1707479,2093/10465
baseline therapy,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,2094/10465
hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol ),C0053917;C1334884,2095/10465
history of recurrent venous thromboembolism,C0455533;C0455533;C0455533;C0455533,2096/10465
magnetic resonance angiography,C0243032,2097/10465
free fatty acids — mmol / liter,,2098/10465
baseline post - bronchodilator % predicted fev  > nmbr % and no concurrent tiotropium,C0168634;C0168634;C1442488;C1442488,2099/10465
id genotype,C0009450;C0600091;C1441613,2100/10465
major coronary,C0205082;C0205164;C4318856;C4521762,2101/10465
cardiac rhythm disorders,C0264886,2102/10465
previous ischemic stroke  n ( % ),C0205156;C1552607,2103/10465
apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),C0003593;C0003593,2104/10465
history of macroalbuminuriat  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2105/10465
high ( > nmbr risk factor ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,2106/10465
psoriasis affecting > nmbr % of body - surface,C0033860;C0033860,2107/10465
asthma duration ( sd )  years,C0004096;C0004096;C2984299;C2984299,2108/10465
glucose metabolism,C0596620,2109/10465
glycated hemoglobin  median ( iqr ),C0017853,2110/10465
blood pressure  mean ± sd mm hg,,2111/10465
fpi  mean ( sd )  pu / mlt,,2112/10465
secondary # nmbr,C0027627;C0027627;C0175668;C0175668;C0205436;C0205436,2113/10465
nmbr . nmbr - nmbr . nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2114/10465
primary pci no .,C0205225;C0439612;C0439631,2115/10465
rectum and sigmoid colon only,C0034896,2116/10465
radial access — no . / total no . ( % ),,2117/10465
oral blood glucose - lowering,C0442027;C4521986,2118/10465
age nmbr + yrs,C0001779;C0001779,2119/10465
> nmbr . nmbr pmol / liter hscrp level,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,2120/10465
other ischaemic heart disease ( non - infarction ),C0010054;C0151744,2121/10465
calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611,2122/10465
a mini - mental state examination  insulin glargine vs standard care,C0451306,2123/10465
country : argentina ( n = nmbr ),C0454664;C1511538,2124/10465
estimated gfr — no . ( % ) nmbr,,2125/10465
received > nmbr prior anti - tnf therapies  n,C1514756,2126/10465
nmbr placebo ( n = nmbr nmbr ),C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2127/10465
standard care n ( % ),C1442989;C2828392,2128/10465
interval from clopidogrel loading  h,C1272706;C1552654;C1552713,2129/10465
severity of copd *  n ( % ),C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,2130/10465
acr deciles,C1412134;C1515941,2131/10465
change at week nmbr,C0392747;C0392747;C0392747;C0392747;C0443172;C0443172;C0443172;C0443172;C1705241;C1705241;C1705241;C1705241;C4319952;C4319952;C4319952;C4319952,2132/10465
europe  israel  or australia,C0015176,2133/10465
low density lipoprotein cholesterol - mg / dltt,C0023824;C0023824;C0023824;C0023824;C0023824;C0023824;C0023824,2134/10465
other dmard use,C0242708;C0242708;C0242708,2135/10465
duration of hypercholesterolemia ( yr ),C0449238;C0449238;C2926735;C2926735,2136/10465
personal relationships,C1552027,2137/10465
heart failure or lvef < nmbr % associated with index acs event,C0018801;C0018802;C4554158,2138/10465
previous venous thromboembolism — no . ( % ),,2139/10465
prior biologic exposure,C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,2140/10465
need for urgent coronary - artery bypass grafting,C0027552;C0027552;C0686904;C0686904,2141/10465
egfr ( ml / min / nmbr - nmbr mz ),C1739039;C3811844;C3812682,2142/10465
egfr ( mdrd )  ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,2143/10465
previous stroke  n ( % ),C0205156;C0205156;C1552607;C1552607,2144/10465
alpha nmbr blockers,C0001641;C0001641,2145/10465
moderate dysfunction,C3274776,2146/10465
tnf - rnmbra ( ng / ml ),C1448177,2147/10465
jejunum,C0022378,2148/10465
neither ace - i nor arb use,C1452534;C1452534;C4284014;C4284014,2149/10465
history of vte * *,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2150/10465
d - dimer level  mean ( sd )  ng / mld,C0060323;C0060323;C0060323;C0060323,2151/10465
gfr ( ml / min per nmbr . nmbr nr ),C0017654;C1424601,2152/10465
diastolic fmmhff ' ),C0012000,2153/10465
diabetes duration  median ( iqr )  years,C0011847;C0011847;C0011849;C0011849,2154/10465
nmbr . nmbr ( nmbr nmbr . nmbr ),C0053917;C1334884,2155/10465
plaque score ( nmbr - nmbr ),C0429153,2156/10465
prior disease,C0332152;C2826257,2157/10465
mean sd fpg  mg / dl,C0444504;C2347634;C2348143,2158/10465
serum ctx ( ng / ml ),C0229671;C0229671;C0229671;C1546774;C1546774;C1546774;C1550100;C1550100;C1550100,2159/10465
baseline triglycerides in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,2160/10465
ff / vi nmbr mg / nmbr mg ( n = nmbr ),C4554348;C4554348,2161/10465
previous anti - tnf therapy  n [ % ],C0205156;C1552607,2162/10465
dronedarone ( n = nmbr ),C0766326,2163/10465
standard ( nmbr ),C1442989;C2828392,2164/10465
age  median ( interquartile range )  y,C0001779,2165/10465
one or more copd exacerbations ( n / n [ % ] ),C0205447,2166/10465
peripheral embolism,C0205100;C0205100,2167/10465
arterial blood pressure  mm hg,C1272641,2168/10465
co - morbidities  a n ( % ),C0009488,2169/10465
oral hypoglycemic drugs only,C0359086;C0359086,2170/10465
p value ( on vs off omt ),C1709380,2171/10465
mucocutaneous,,2172/10465
any new anti - hyperglycemic rx,C0205314;C0205314;C0205314,2173/10465
metsyn with ldl > nmbr . nmbr mg / dl,,2174/10465
severe or worse airflow limitation,C0205082;C4050465;C4050466,2175/10465
periprocedural anticoagulant,C0003280;C0848112;C3536711,2176/10465
lsms difference ( nmbr % ci ) nmbr,C1705241;C1705242,2177/10465
age  y sex  no . ( % ),C0001779,2178/10465
blood eosinophil,C0014467,2179/10465
pah classification — no . ( % ),,2180/10465
short - acting bnmbr - agonists,C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002,2181/10465
fevnmbr reversibility  pre - / post - albuterol  %,C0449261,2182/10465
ischemia on cecg ( n = nmbr  nmbr ),C0022116;C4321499,2183/10465
ularitide n / n ( % ),C0077910,2184/10465
three of seven risk factors,C0205449;C0205449,2185/10465
moderately high risk without atherosclerotic vascular disease *,C0205081;C0205081;C0205081;C0205081;C1881878;C1881878;C1881878;C1881878;C4085643;C4085643;C4085643;C4085643;C4321491;C4321491;C4321491;C4321491,2186/10465
randomised to canakinumab nmbr mg,,2187/10465
ff nmbr pgod,C4554348;C4554348,2188/10465
fevnmbr post - bronchodilator  % predicted normal,C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594,2189/10465
migraine — no . ( % ) $,,2190/10465
hypertension — no . / total no . ( % ),,2191/10465
randomized to active yitamin e,C0034656;C0034656;C0034656;C3815594;C3815594;C3815594,2192/10465
low risk and more symptoms ( group b ),C3272281;C3538919,2193/10465
high risk,C0332167;C3272283;C4050568;C4319571,2194/10465
carotid artery diseaset,C0007272;C0162859,2195/10465
cholesterol — mmol / liter,,2196/10465
fasting plasma glucose,C0015663;C0015663,2197/10465
daily activities,C0871707,2198/10465
extended - duration enoxaparin ( n = nmbr ),C0231448;C0231449;C0439792,2199/10465
dasnmbr - nmbr ( esr ),C0053917;C1334884,2200/10465
associated with corrected - congenital shunts,C0332281;C0332281;C0332281;C0332281;C0332281;C0332281,2201/10465
traditional nsaid use,C3897349;C3897349,2202/10465
baseline albumin : < nmbr,C0168634;C1442488,2203/10465
high - risk cvd  n ( % ),C0332167;C3272283;C4050568;C4319571,2204/10465
pro / pro homozygotes,C1120626,2205/10465
sulfasalazine ( mean dose : nmbr . nmbr g / day ),C0036078,2206/10465
> nmbr years eze / simva baseline ldl - c,C0053917;C0053917;C1334884;C1334884,2207/10465
< nmbr % predicted arr ( n = nmbr  nmbr ),C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,2208/10465
pe associated with dvt at diagnosis,C0070939;C1880476;C4284304,2209/10465
baseline hbanmbrc,C0168634;C1442488,2210/10465
renal function < nmbr egfr  ml / min / nmbr . nmbr mnmbr,C0232804,2211/10465
blood eosinophil concentration  nmbr cells per l,C0427728;C0699870;C1313904;C0014467;C0014467;C0014467,2212/10465
less severenmbr,C0439092;C0547044,2213/10465
cardiovascular risk,C0007226;C0007226;C3887460;C3887460,2214/10465
prehospital ticagrelor ( n = nmbr ),C1999375,2215/10465
symptoms of atrial fibrillation in the nmbr months before randomiza -,C0683368;C0683368;C0683368;C1457887;C1457887;C1457887,2216/10465
perindopril,C0136123,2217/10465
tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr ),C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,2218/10465
symptom onset to hospital admission,C4086878,2219/10465
ldl - c ( measured ) *,,2220/10465
rerapamil - sr strategy ( n = nmbr ),C0753208;C1709991;C3813610;C3890900;C3891546,2221/10465
erosion score  mean nmbr sd,C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,2222/10465
valve surgery  n ( % ),C0184252;C0184252;C0184252;C0184252;C1186983;C1186983;C1186983;C1186983;C1704414;C1704414;C1704414;C1704414;C3888056;C3888056;C3888056;C3888056,2223/10465
ticagrelor nmbr mg nmbr year km ( % ),C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375,2224/10465
north america ( plus australia and new zealand ),C0028405,2225/10465
calcium antagonist — no . ( % ),,2226/10465
penetrating disease  %,C0205321,2227/10465
non - drug - eluting stent,C1518422,2228/10465
number of exacerbations in the past nmbr months,C0237753;C0449788,2229/10465
potassium supplement,C0304475,2230/10465
age group,C0027362;C2348001,2231/10465
congestive heart failure ( chf ) ( in past nmbr weeks ),C0018802,2232/10465
platelet count  x nmbr mmnmbr,C0032181;C1287267,2233/10465
other supraventricular tachycardia,C0039240;C1963244;C3815188,2234/10465
egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] ),C1739039;C3811844;C3812682,2235/10465
mean bmi  kg / mnmbr,C0444504;C2347634;C2348143,2236/10465
* * * unstable angina,,2237/10465
rate ratio,C0871208;C0871208;C1521828;C1521828,2238/10465
recurrent vte ( statin use vs non - use ),C1455761;C2945760,2239/10465
saxagliptin nmbr mg ( n = nmbr  nmbr ),C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,2240/10465
irregular or ulcerated ica p ) laque : [ :,C0205271,2241/10465
extreme tortuosity,C0205403;C3641272;C4085555,2242/10465
angina status — no . ( % ),,2243/10465
p value nmbr . nmbr,C1709380;C1709380,2244/10465
nonaspirin antiplatelet,C0722138,2245/10465
antihyperglycemictherapies  %,,2246/10465
geographic distribution - no . ( % ),C0681686,2247/10465
conventional synthetic dmard use at baseline,C0439858;C0439858;C0439858;C0439858;C0439858;C0439858,2248/10465
statins 一 no . ( % ),,2249/10465
at six weeks,C0205452,2250/10465
angiographic data and treatment :,C0002978;C0002978;C0002978,2251/10465
clinical indication at the index procedure  n ( % ),C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,2252/10465
mean bdi focal score ( sd ),C3533236;C3533236;C3533236;C3533236,2253/10465
cabg during index hospitalization,C0010055;C0010055;C0010055;C0010055;C0010055,2254/10465
pci for index event,C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621,2255/10465
concomitant drug treatment,C0521115;C0521115,2256/10465
third primary ( change in updrs score / wk  wk nmbr - nmbr ),C0205437;C0205437;C0205437,2257/10465
implanted pacemaker,C0848753,2258/10465
concomitant asthma medications  n ( % ),C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115,2259/10465
hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol ),C0053917;C1334884,2260/10465
uacr not available,,2261/10465
ret / abx - facil . pci,C0389252,2262/10465
severity of copd  airflow limitation  n ( % ),C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,2263/10465
claudication only,C0021775;C0021775;C0311395;C0311395;C1456822;C1456822,2264/10465
mean % predicted dlco * ( sd ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,2265/10465
titre ( u / ml ) t,C0475208,2266/10465
treatment before admission ( % ),C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,2267/10465
overall quality of life,C3641830,2268/10465
no baseline corticosteroids,C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,2269/10465
high on - treatment platelet reactivity *,C0205250;C0205250;C0205250;C0205250;C0205250;C0205250;C0205250;C1299351;C1299351;C1299351;C1299351;C1299351;C1299351;C1299351;C2700149;C2700149;C2700149;C2700149;C2700149;C2700149;C2700149;C3887512;C3887512;C3887512;C3887512;C3887512;C3887512;C3887512;C3889660;C3889660;C3889660;C3889660;C3889660;C3889660;C3889660;C4321237;C4321237;C4321237;C4321237;C4321237;C4321237;C4321237;C4522209;C4522209;C4522209;C4522209;C4522209;C4522209;C4522209,2270/10465
potassium ( meql )  mean + sd  available for nmbr patients,C0032821;C0202194;C0304475;C0597277;C3714637,2271/10465
all patients with opg n - nmbr,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,2272/10465
urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),C2362049,2273/10465
cardiac rhythm disorder at baseline yes,C0264886;C0264886;C0264886;C0264886;C0264886;C0264886,2274/10465
islander,,2275/10465
left circumflex coronary artery,C0226037,2276/10465
risk category ( points ),C0035647;C0035647;C4552904;C4552904,2277/10465
nihss at randomization  nmbr - nmbr,C1697238,2278/10465
cilostazol,C0055729,2279/10465
creatinine clearance category  ml / min  no . ( % ) b,C0812399;C0812399,2280/10465
tg > nmbr mg / dl  n ( ° / o ),,2281/10465
chf on losartan ( % ),C0018802,2282/10465
comorbidities  %,C0009488,2283/10465
prior lipid - lowering agent use,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,2284/10465
iwqol - lite total score ( arbitrary units ) #,C2964552,2285/10465
absolute change,C1549031,2286/10465
gusto moderate / severe,,2287/10465
ls mean difference ( se ) vs placebo,C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,2288/10465
stent implanted — no . ( % ),,2289/10465
eze / simva ( „ = nmbr },,2290/10465
low eosinophil subgroup (  nmbr / ml ) ( n = nmbr ),C0205251;C0205251;C1550472;C1550472;C3890211;C3890211;C4048187;C4048187;C4321351;C4321351;C4522223;C4522223,2291/10465
alaska native,C0682125,2292/10465
| interactior nmbr p,C0053917;C1334884,2293/10465
number ( s ) of features present,C0237753;C0449788,2294/10465
extent of disease — no . / total no . ( % ) § ^ |,,2295/10465
eze / simva nmbr / nmbr mg n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2296/10465
bivalirudin,C0168273,2297/10465
two arm,C0205448;C0205448;C0205448,2298/10465
metreo modified intention - to - treat population §,,2299/10465
any blood pressure medications ( % ),C0849164;C0849164;C0849164;C0849164;C0005823;C0005823;C0005823;C0005823;C1271104;C1271104;C1271104;C1271104;C1272641;C1272641;C1272641;C1272641,2300/10465
p  net difference,C0369773;C2603361,2301/10465
statin users ( n = nmbr ),C0360714,2302/10465
simplified disease activity index score ( nmbr - nmbr ),C3869582;C3869582,2303/10465
calcium channel,C0006685,2304/10465
level — no . ( % ),,2305/10465
no regular consumption,C0205272;C0205272,2306/10465
nmbr / nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884,2307/10465
time from randomization to pci ( non - st - elevation mi )  h,C0040223;C3541383,2308/10465
nmbre < nmbr %  n ( % ),,2309/10465
prior pacemaker  n ( % ),C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257,2310/10465
non - detectable / unknown  n ( % ),C1518422;C1518422;C1518422,2311/10465
individuals without diabetes  n = nmbr  nmbr,C0027361;C0027361;C0237401;C0237401,2312/10465
post - fibrinolysis angioplasty ( n = nmbr ),C0687676;C0687676;C0687676;C0687676;C1704687;C1704687;C1704687;C1704687;C3469826;C3469826;C3469826;C3469826,2313/10465
aerobic activity,C0001701,2314/10465
pulse pressure,C0949236,2315/10465
laboratory measures,C0022877;C3244292;C4283904,2316/10465
deep - vein thrombosis ( % ),C0149871,2317/10465
cardiovascu lar subg roup,C1419115;C3814448,2318/10465
greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr,C0439093,2319/10465
statin  n ( % ),C0360714,2320/10465
location of infarction,C0450429;C1515974;C4284930;C4284931,2321/10465
infliximab - experienced ( n = nmbr ),C0666743,2322/10465
time since first copd diagnosis ( years ),C0040223;C3541383,2323/10465
potassium — mmol / liter,,2324/10465
rivaroxaban ( n = nmbr ),C1739768,2325/10465
investigator - determined myocardial infarction,C0035173;C0035173;C0035173;C0035173;C0035173,2326/10465
time from first eval,C0040223;C0040223;C0040223;C0040223;C3541383;C3541383;C3541383;C3541383,2327/10465
diagnosis of heterozygous familial hypercholester,C0011900;C0011900;C1704338;C1704338;C1704656;C1704656,2328/10465
baseline crp ( mg / dl ),C0168634;C0168634;C1442488;C1442488,2329/10465
average of maximum far wall cimt ( mm ),C1510992;C1510992;C1510992;C2825518;C2825518;C2825518,2330/10465
hispanic ethnicity,C0086409;C0086409,2331/10465
other vasodilator,C0042402;C3537240,2332/10465
maintenance dose,C3714445,2333/10465
thienopyridine type,C1120149;C1120149,2334/10465
perfusion defectsatinclusion,C0031001;C4281794,2335/10465
dasnmbr - esr remission,C3811131;C3811131,2336/10465
no . of panents . total no . nmbr % ),,2337/10465
disease activity outcomes ( itt population ) week nmbr,C0679250;C0679250;C0679250;C0679250;C0679250;C0679250;C0679250;C3542417;C3542417;C3542417;C3542417;C3542417;C3542417;C3542417;C1292728,2338/10465
fluticasone furoate and vilanterol ( n = nmbr ),C1948374,2339/10465
any infarct,C0021308,2340/10465
apolipoprotein a - i *,C0085201;C1677784,2341/10465
current smoking — no . / total no . ( % ),,2342/10465
miami k antagonist received,C1551421;C1551421,2343/10465
rivastigmine,C0649350,2344/10465
europa ( n = nmbrlnmbr ),C0242751,2345/10465
lung function  mean,C0035245,2346/10465
physician ' s global assessment of disease activity ( nmbr - nmbr mm vas )  mean ( sd ),C4050369,2347/10465
nmbr - nmbr ( very severe ),C0053917;C1334884,2348/10465
high - risk clinical features,C0332167;C3272283;C4050568;C4319571,2349/10465
second primary composite outcome,C0205436;C0205436;C0205436;C0205436;C0205436;C0205436;C0457385;C0457385;C0457385;C0457385;C0457385;C0457385;C0565930;C0565930;C0565930;C0565930;C0565930;C0565930;C1561503;C1561503;C1561503;C1561503;C1561503;C1561503;C1705190;C1705190;C1705190;C1705190;C1705190;C1705190,2350/10465
baseline % predicted fevnmbr,C0168634;C0168634;C1442488;C1442488,2351/10465
treatment characteristics,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,2352/10465
digoxin at last follow - up,C0012265;C0012265;C0012265;C0012265,2353/10465
both impaired glucose tolerance and impaired fasting glucose tolerance — no .,,2354/10465
ez / simva < % >,C0206578,2355/10465
sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0085805,2356/10465
# of prior bdmards,,2357/10465
acute reaction,C0205178,2358/10465
ulcers / gangrene,C0041582,2359/10465
fasting plasma glucose ( mmol / l ),C0015663;C0015663,2360/10465
other teaes,,2361/10465
alcohol intake,C0001948,2362/10465
change from baseline ( % ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,2363/10465
ileum only,C0020885;C0020885,2364/10465
anti - tnf - ir patients,C1448177;C1448177;C1448177,2365/10465
north america plus australia and new zealand,C0028405,2366/10465
medial - distal - diag,C0205098;C0205098,2367/10465
bw at nmbr weeks  kg +,C0005910;C0005910;C0006041;C0006041;C2986891;C2986891,2368/10465
haemoglobin ( mmol / l ),C0019046,2369/10465
severity ofcopd ( goldnmbr )  n ( % ),C0439793;C0522510,2370/10465
prior stroke — no . ( % ),,2371/10465
adalimumab ( n = nmbr ),C1122087,2372/10465
aliskiren dm = nmbr non - dm = nmbr,C1120110;C1120110,2373/10465
previous cabg ( before index acs ) *,C0205156;C1552607,2374/10465
number of patients ( % ) or mean 士 sd,,2375/10465
severity of copd  n ( % ) ( gold nmbr ) : moderate,C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,2376/10465
western friroce,C1705493,2377/10465
baseline lipids  mean ± sd ( mmol / nmbr ),,2378/10465
baseline calcium yes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,2379/10465
cardiac mediations,C0018787;C1522601,2380/10465
large vessel,C0225990,2381/10465
no . of treated vessels,,2382/10465
sinus rhythm at baseline,C0232201;C0232201,2383/10465
ipah / hpah,C0152171;C0152171;C0152171,2384/10465
ccs class §,,2385/10465
antithrombotic and anticoagulant medications,,2386/10465
ixeqnmbrw  n = nmbr,,2387/10465
warfarin group ( n = nmbr ),C0043031;C0043031;C0043031;C0043031;C0043031;C0043031,2388/10465
white - cell count — xnmbr_nmbr / liter,,2389/10465
mean % predicted fvc ( sd ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,2390/10465
only cerebrovascular disease,C0205171;C1720467,2391/10465
three or more agents,C0205449,2392/10465
msfc timed nmbr - foot walk test  median seconds,,2393/10465
mean ( sd ) baseline scores,C0444504;C2347634;C2348143,2394/10465
patients with > nmbr % ■ nmbr ml increase in fevnmbr post - bronchodilator ( % ),,2395/10465
meglitinide,C0065880,2396/10465
prior tobacco use  n ( % ),C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,2397/10465
graft occlusionsa,C0181074;C0332835;C1961139,2398/10465
ascot - lla,C0718674,2399/10465
cortical only,C0001613;C0001613;C0007776;C0007776;C0022655;C0022655,2400/10465
key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ nmbr of the indicated char least - square means  except tc an note : all treatment by subgroup,,2401/10465
prior disease - modifying drugs resulting in inadequate response — mean no . / patient,,2402/10465
extent of disease,C0449279;C4553144,2403/10465
candesartan group ( n = nmbr ),C0717550;C0717550;C0717550;C0717550;C0717550;C0717550,2404/10465
rivaroxaban alone ( n = nmbr ),C1739768,2405/10465
